IEX 10-Q Quarterly Report March 31, 2023 | Alphaminr
ALPHAMINR

IEX 10-Q Quarter ended March 31, 2023

Balance Sheet
Cash Flow
Income Statement
Debt
IDEX CORP /DE/
10-Qs and 10-Ks
10-K
 		Fiscal year ended Dec. 31, 2024
10-Q
 		Quarter ended Sept. 30, 2024
10-Q
 		Quarter ended June 30, 2024
10-Q
 		Quarter ended March 31, 2024
10-K
 		Fiscal year ended Dec. 31, 2023
10-Q
 		Quarter ended Sept. 30, 2023
10-Q
 		Quarter ended June 30, 2023
10-Q
 		Quarter ended March 31, 2023
10-K
 		Fiscal year ended Dec. 31, 2022
10-Q
 		Quarter ended Sept. 30, 2022
10-Q
 		Quarter ended June 30, 2022
10-Q
 		Quarter ended March 31, 2022
10-K
 		Fiscal year ended Dec. 31, 2021
10-Q
 		Quarter ended Sept. 30, 2021
10-Q
 		Quarter ended June 30, 2021
10-Q
 		Quarter ended March 31, 2021
10-K
 		Fiscal year ended Dec. 31, 2020
10-Q
 		Quarter ended Sept. 30, 2020
10-Q
 		Quarter ended June 30, 2020
10-Q
 		Quarter ended March 31, 2020
10-K
 		Fiscal year ended Dec. 31, 2019
10-Q
 		Quarter ended Sept. 30, 2019
10-Q
 		Quarter ended June 30, 2019
10-Q
 		Quarter ended March 31, 2019
10-K
 		Fiscal year ended Dec. 31, 2018
10-Q
 		Quarter ended Sept. 30, 2018
10-Q
 		Quarter ended June 30, 2018
10-Q
 		Quarter ended March 31, 2018
10-K
 		Fiscal year ended Dec. 31, 2017
10-Q
 		Quarter ended Sept. 30, 2017
10-Q
 		Quarter ended June 30, 2017
10-Q
 		Quarter ended March 31, 2017
10-K
 		Fiscal year ended Dec. 31, 2016
10-Q
 		Quarter ended Sept. 30, 2016
10-Q
 		Quarter ended June 30, 2016
10-Q
 		Quarter ended March 31, 2016
10-K
 		Fiscal year ended Dec. 31, 2015
10-Q
 		Quarter ended Sept. 30, 2015
10-Q
 		Quarter ended June 30, 2015
10-Q
 		Quarter ended March 31, 2015
10-K
 		Fiscal year ended Dec. 31, 2014
10-Q
 		Quarter ended Sept. 30, 2014
10-Q
 		Quarter ended June 30, 2014
10-Q
 		Quarter ended March 31, 2014
10-K
 		Fiscal year ended Dec. 31, 2013
10-Q
 		Quarter ended Sept. 30, 2013
10-Q
 		Quarter ended June 30, 2013
10-Q
 		Quarter ended March 31, 2013
10-K
 		Fiscal year ended Dec. 31, 2012
10-Q
 		Quarter ended Sept. 30, 2012
10-Q
 		Quarter ended June 30, 2012
10-Q
 		Quarter ended March 31, 2012
10-K
 		Fiscal year ended Dec. 31, 2011
10-Q
 		Quarter ended Sept. 30, 2011
10-Q
 		Quarter ended June 30, 2011
10-Q
 		Quarter ended March 31, 2011
10-K
 		Fiscal year ended Dec. 31, 2010
10-Q
 		Quarter ended Sept. 30, 2010
10-Q
 		Quarter ended June 30, 2010
10-Q
 		Quarter ended March 31, 2010
10-K
 		Fiscal year ended Dec. 31, 2009
PROXIES
DEF 14A
 		Filed on March 26, 2025
DEF 14A
 		Filed on March 26, 2024
DEF 14A
 		Filed on April 4, 2023
DEF 14A
 		Filed on March 23, 2022
DEF 14A
 		Filed on March 23, 2021
DEF 14A
 		Filed on March 20, 2020
DEF 14A
 		Filed on March 22, 2019
DEF 14A
 		Filed on March 16, 2018
DEF 14A
 		Filed on March 17, 2017
DEF 14A
 		Filed on March 2, 2016
DEF 14A
 		Filed on March 2, 2015
DEF 14A
 		Filed on March 3, 2014
DEF 14A
 		Filed on Feb. 26, 2013
DEF 14A
 		Filed on March 7, 2012
DEF 14A
 		Filed on March 4, 2011
DEF 14A
 		Filed on March 5, 2010
iex-20230331
false 2023 Q1 0000832101 12/31 http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent 0000832101 2023-01-01 2023-03-31 0000832101 2023-04-21 xbrli:shares 0000832101 2023-03-31 iso4217:USD 0000832101 2022-12-31 iso4217:USD xbrli:shares 0000832101 2022-01-01 2022-03-31 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-12-31 0000832101 us-gaap:RetainedEarningsMember 2022-12-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000832101 us-gaap:TreasuryStockCommonMember 2022-12-31 0000832101 us-gaap:ParentMember 2022-12-31 0000832101 us-gaap:NoncontrollingInterestMember 2022-12-31 0000832101 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000832101 us-gaap:ParentMember 2023-01-01 2023-03-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-03-31 0000832101 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-03-31 0000832101 us-gaap:RetainedEarningsMember 2023-03-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-03-31 0000832101 us-gaap:TreasuryStockCommonMember 2023-03-31 0000832101 us-gaap:ParentMember 2023-03-31 0000832101 us-gaap:NoncontrollingInterestMember 2023-03-31 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2021-12-31 0000832101 us-gaap:RetainedEarningsMember 2021-12-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000832101 us-gaap:TreasuryStockCommonMember 2021-12-31 0000832101 us-gaap:ParentMember 2021-12-31 0000832101 us-gaap:NoncontrollingInterestMember 2021-12-31 0000832101 2021-12-31 0000832101 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000832101 us-gaap:ParentMember 2022-01-01 2022-03-31 0000832101 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-03-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-03-31 0000832101 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-03-31 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-03-31 0000832101 us-gaap:RetainedEarningsMember 2022-03-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2022-03-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-03-31 0000832101 us-gaap:TreasuryStockCommonMember 2022-03-31 0000832101 us-gaap:ParentMember 2022-03-31 0000832101 us-gaap:NoncontrollingInterestMember 2022-03-31 0000832101 2022-03-31 0000832101 iex:NexsightLLCMember 2022-02-28 2022-02-28 0000832101 iex:NexsightLLCMember 2022-02-28 0000832101 us-gaap:TradeNamesMember iex:NexsightLLCMember 2022-02-28 2022-02-28 0000832101 iex:NexsightLLCMember us-gaap:CustomerRelationshipsMember 2022-02-28 2022-02-28 0000832101 us-gaap:SoftwareDevelopmentMember iex:NexsightLLCMember 2022-02-28 2022-02-28 0000832101 iex:KZValveMember 2022-05-02 2022-05-02 0000832101 iex:KZValveMember 2022-05-02 0000832101 us-gaap:TradeNamesMember iex:KZValveMember 2022-05-02 2022-05-02 0000832101 iex:KZValveMember us-gaap:CustomerRelationshipsMember 2022-05-02 2022-05-02 0000832101 us-gaap:UnpatentedTechnologyMember iex:KZValveMember 2022-05-02 2022-05-02 0000832101 iex:MuonLLCMember 2022-11-18 2022-11-18 0000832101 iex:MuonLLCMember iex:CashOnHandMember 2022-11-18 2022-11-18 0000832101 iex:MuonLLCMember us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2022-11-18 2022-11-18 0000832101 iex:MuonLLCMember us-gaap:LineOfCreditMember us-gaap:SecuredDebtMember 2022-11-18 2022-11-18 0000832101 iex:MuonLLCMember 2022-11-18 0000832101 iex:MuonLLCMember us-gaap:TradeNamesMember 2022-11-18 2022-11-18 0000832101 iex:MuonLLCMember us-gaap:CustomerRelationshipsMember 2022-11-18 2022-11-18 0000832101 iex:MuonLLCMember us-gaap:UnpatentedTechnologyMember 2022-11-18 2022-11-18 0000832101 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0000832101 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 iex:segment 0000832101 iex:FluidAndMeteringTechnologiesMember 2023-01-01 2023-03-31 0000832101 iex:FluidAndMeteringTechnologiesMember 2022-01-01 2022-03-31 0000832101 us-gaap:IntersegmentEliminationMember iex:FluidAndMeteringTechnologiesMember 2023-01-01 2023-03-31 0000832101 us-gaap:IntersegmentEliminationMember iex:FluidAndMeteringTechnologiesMember 2022-01-01 2022-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2023-01-01 2023-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2022-01-01 2022-03-31 0000832101 iex:HealthAndScienceTechnologiesMember 2023-01-01 2023-03-31 0000832101 iex:HealthAndScienceTechnologiesMember 2022-01-01 2022-03-31 0000832101 us-gaap:IntersegmentEliminationMember iex:HealthAndScienceTechnologiesMember 2023-01-01 2023-03-31 0000832101 us-gaap:IntersegmentEliminationMember iex:HealthAndScienceTechnologiesMember 2022-01-01 2022-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2023-01-01 2023-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2022-01-01 2022-03-31 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2023-01-01 2023-03-31 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2022-01-01 2022-03-31 0000832101 us-gaap:IntersegmentEliminationMember iex:FireAndSafetyDiversifiedProductsMember 2023-01-01 2023-03-31 0000832101 us-gaap:IntersegmentEliminationMember iex:FireAndSafetyDiversifiedProductsMember 2022-01-01 2022-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2023-01-01 2023-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2022-01-01 2022-03-31 0000832101 us-gaap:IntersegmentEliminationMember 2023-01-01 2023-03-31 0000832101 us-gaap:IntersegmentEliminationMember 2022-01-01 2022-03-31 0000832101 us-gaap:OperatingSegmentsMember 2023-01-01 2023-03-31 0000832101 us-gaap:OperatingSegmentsMember 2022-01-01 2022-03-31 0000832101 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-03-31 0000832101 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-03-31 0000832101 iex:FluidAndMeteringTechnologiesMember 2023-03-31 0000832101 iex:FluidAndMeteringTechnologiesMember 2022-12-31 0000832101 iex:HealthAndScienceTechnologiesMember 2023-03-31 0000832101 iex:HealthAndScienceTechnologiesMember 2022-12-31 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2023-03-31 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2022-12-31 0000832101 us-gaap:CorporateNonSegmentMember 2023-03-31 0000832101 us-gaap:CorporateNonSegmentMember 2022-12-31 0000832101 iex:PumpsMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2023-01-01 2023-03-31 0000832101 iex:PumpsMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2022-01-01 2022-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:Water1Member iex:FluidAndMeteringTechnologiesMember 2023-01-01 2023-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:Water1Member iex:FluidAndMeteringTechnologiesMember 2022-01-01 2022-03-31 0000832101 iex:EnergyMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2023-01-01 2023-03-31 0000832101 iex:EnergyMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2022-01-01 2022-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:AgricultureMember 2023-01-01 2023-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:AgricultureMember 2022-01-01 2022-03-31 0000832101 iex:ValvesMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2023-01-01 2023-03-31 0000832101 iex:ValvesMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2022-01-01 2022-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:ScientificFluidicsandOpticsMember iex:HealthAndScienceTechnologiesMember 2023-01-01 2023-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:ScientificFluidicsandOpticsMember iex:HealthAndScienceTechnologiesMember 2022-01-01 2022-03-31 0000832101 iex:PerformancePneumaticTechnologiesMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2023-01-01 2023-03-31 0000832101 iex:PerformancePneumaticTechnologiesMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2022-01-01 2022-03-31 0000832101 iex:SealingSolutionsMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2023-01-01 2023-03-31 0000832101 iex:SealingSolutionsMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2022-01-01 2022-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:MaterialProcessingTechnologiesMember 2023-01-01 2023-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:MaterialProcessingTechnologiesMember 2022-01-01 2022-03-31 0000832101 iex:MicropumpMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2023-01-01 2023-03-31 0000832101 iex:MicropumpMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2022-01-01 2022-03-31 0000832101 iex:FireandSafetyMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2023-01-01 2023-03-31 0000832101 iex:FireandSafetyMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2022-01-01 2022-03-31 0000832101 iex:DispensingMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2023-01-01 2023-03-31 0000832101 iex:DispensingMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2022-01-01 2022-03-31 0000832101 iex:BandItMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2023-01-01 2023-03-31 0000832101 iex:BandItMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2022-01-01 2022-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember country:US 2023-01-01 2023-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember country:US 2023-01-01 2023-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember country:US 2023-01-01 2023-03-31 0000832101 us-gaap:OperatingSegmentsMember country:US 2023-01-01 2023-03-31 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2023-01-01 2023-03-31 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2023-01-01 2023-03-31 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2023-01-01 2023-03-31 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-03-31 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2023-01-01 2023-03-31 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2023-01-01 2023-03-31 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2023-01-01 2023-03-31 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember srt:AsiaMember 2023-01-01 2023-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember srt:AsiaMember 2023-01-01 2023-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember srt:AsiaMember 2023-01-01 2023-03-31 0000832101 us-gaap:OperatingSegmentsMember srt:AsiaMember 2023-01-01 2023-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:OtherGeographicalAreasMember 2023-01-01 2023-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:OtherGeographicalAreasMember 2023-01-01 2023-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:OtherGeographicalAreasMember 2023-01-01 2023-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember 2023-01-01 2023-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember country:US 2022-01-01 2022-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember country:US 2022-01-01 2022-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember country:US 2022-01-01 2022-03-31 0000832101 us-gaap:OperatingSegmentsMember country:US 2022-01-01 2022-03-31 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2022-01-01 2022-03-31 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2022-01-01 2022-03-31 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2022-01-01 2022-03-31 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-03-31 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2022-01-01 2022-03-31 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2022-01-01 2022-03-31 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2022-01-01 2022-03-31 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember srt:AsiaMember 2022-01-01 2022-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember srt:AsiaMember 2022-01-01 2022-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember srt:AsiaMember 2022-01-01 2022-03-31 0000832101 us-gaap:OperatingSegmentsMember srt:AsiaMember 2022-01-01 2022-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:OtherGeographicalAreasMember 2022-01-01 2022-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:OtherGeographicalAreasMember 2022-01-01 2022-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:OtherGeographicalAreasMember 2022-01-01 2022-03-31 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember 2022-01-01 2022-03-31 0000832101 us-gaap:ProductConcentrationRiskMember us-gaap:TransferredAtPointInTimeMember us-gaap:RevenueFromContractWithCustomerMember 2023-01-01 2023-03-31 xbrli:pure 0000832101 us-gaap:ProductConcentrationRiskMember us-gaap:TransferredAtPointInTimeMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-03-31 0000832101 us-gaap:ProductConcentrationRiskMember us-gaap:TransferredOverTimeMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-03-31 0000832101 us-gaap:ProductConcentrationRiskMember us-gaap:TransferredOverTimeMember us-gaap:RevenueFromContractWithCustomerMember 2023-01-01 2023-03-31 0000832101 iex:BilledReceivablesMember 2023-03-31 0000832101 iex:BilledReceivablesMember 2022-12-31 0000832101 us-gaap:PatentsMember 2023-03-31 0000832101 us-gaap:PatentsMember 2023-01-01 2023-03-31 0000832101 us-gaap:PatentsMember 2022-12-31 0000832101 us-gaap:TradeNamesMember 2023-03-31 0000832101 us-gaap:TradeNamesMember 2023-01-01 2023-03-31 0000832101 us-gaap:TradeNamesMember 2022-12-31 0000832101 us-gaap:CustomerRelationshipsMember 2023-03-31 0000832101 us-gaap:CustomerRelationshipsMember 2023-01-01 2023-03-31 0000832101 us-gaap:CustomerRelationshipsMember 2022-12-31 0000832101 us-gaap:UnpatentedTechnologyMember 2023-03-31 0000832101 us-gaap:UnpatentedTechnologyMember 2023-01-01 2023-03-31 0000832101 us-gaap:UnpatentedTechnologyMember 2022-12-31 0000832101 us-gaap:SoftwareDevelopmentMember 2023-03-31 0000832101 us-gaap:SoftwareDevelopmentMember 2023-01-01 2023-03-31 0000832101 us-gaap:SoftwareDevelopmentMember 2022-12-31 0000832101 iex:BanjoTradeNameMember 2023-03-31 0000832101 iex:BanjoTradeNameMember 2022-12-31 0000832101 iex:AkronBrasstradenameMember 2023-03-31 0000832101 iex:AkronBrasstradenameMember 2022-12-31 0000832101 us-gaap:SeniorNotesMember iex:ThreePointTwoPercentSeniorNotesMember 2023-03-31 0000832101 us-gaap:SeniorNotesMember iex:ThreePointTwoPercentSeniorNotesMember 2022-12-31 0000832101 us-gaap:SeniorNotesMember iex:ThreePointThreeSevenPercentSeniorNotesMember 2023-03-31 0000832101 us-gaap:SeniorNotesMember iex:ThreePointThreeSevenPercentSeniorNotesMember 2022-12-31 0000832101 us-gaap:SeniorNotesMember iex:ThreePointZeroPercentSeniorNotesDueMay2030Member 2023-03-31 0000832101 us-gaap:SeniorNotesMember iex:ThreePointZeroPercentSeniorNotesDueMay2030Member 2022-12-31 0000832101 us-gaap:SeniorNotesMember iex:TwoPointSixTwoFivePercentSeniorNotesDue2031Member 2023-03-31 0000832101 us-gaap:SeniorNotesMember iex:TwoPointSixTwoFivePercentSeniorNotesDue2031Member 2022-12-31 0000832101 us-gaap:RevolvingCreditFacilityMember 2023-03-31 0000832101 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2023-03-31 0000832101 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2022-12-31 0000832101 us-gaap:LineOfCreditMember us-gaap:SecuredDebtMember 2023-03-31 0000832101 us-gaap:LineOfCreditMember us-gaap:SecuredDebtMember 2022-12-31 0000832101 us-gaap:MutualFundMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000832101 us-gaap:MutualFundMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000832101 us-gaap:MutualFundMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2023-03-31 0000832101 us-gaap:MutualFundMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000832101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-03-31 0000832101 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-03-31 0000832101 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:EquitySecuritiesMember 2023-03-31 0000832101 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-03-31 0000832101 us-gaap:MutualFundMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000832101 us-gaap:MutualFundMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000832101 us-gaap:MutualFundMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0000832101 us-gaap:MutualFundMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000832101 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-03-31 0000832101 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0000832101 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-03-31 0000832101 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 iex:option 0000832101 us-gaap:BuildingMember 2023-03-31 0000832101 us-gaap:BuildingMember 2022-12-31 0000832101 us-gaap:EquipmentMember 2023-03-31 0000832101 us-gaap:EquipmentMember 2022-12-31 0000832101 iex:BuildingAndEquipmentMember 2023-03-31 0000832101 iex:BuildingAndEquipmentMember 2022-12-31 0000832101 us-gaap:VehiclesMember 2023-03-31 0000832101 us-gaap:VehiclesMember 2022-12-31 0000832101 us-gaap:EmployeeSeveranceMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2023-01-01 2023-03-31 0000832101 us-gaap:FacilityClosingMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2023-01-01 2023-03-31 0000832101 us-gaap:EmployeeSeveranceMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2023-01-01 2023-03-31 0000832101 us-gaap:FacilityClosingMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2023-01-01 2023-03-31 0000832101 us-gaap:EmployeeSeveranceMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2023-01-01 2023-03-31 0000832101 us-gaap:FacilityClosingMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2023-01-01 2023-03-31 0000832101 us-gaap:EmployeeSeveranceMember us-gaap:CorporateNonSegmentMember 2023-01-01 2023-03-31 0000832101 us-gaap:CorporateNonSegmentMember us-gaap:FacilityClosingMember 2023-01-01 2023-03-31 0000832101 us-gaap:EmployeeSeveranceMember 2023-01-01 2023-03-31 0000832101 us-gaap:FacilityClosingMember 2023-01-01 2023-03-31 0000832101 us-gaap:EmployeeSeveranceMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2022-01-01 2022-03-31 0000832101 us-gaap:FacilityClosingMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2022-01-01 2022-03-31 0000832101 us-gaap:EmployeeSeveranceMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2022-01-01 2022-03-31 0000832101 us-gaap:FacilityClosingMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2022-01-01 2022-03-31 0000832101 us-gaap:EmployeeSeveranceMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2022-01-01 2022-03-31 0000832101 us-gaap:FacilityClosingMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2022-01-01 2022-03-31 0000832101 us-gaap:EmployeeSeveranceMember us-gaap:CorporateNonSegmentMember 2022-01-01 2022-03-31 0000832101 us-gaap:CorporateNonSegmentMember us-gaap:FacilityClosingMember 2022-01-01 2022-03-31 0000832101 us-gaap:EmployeeSeveranceMember 2022-01-01 2022-03-31 0000832101 us-gaap:FacilityClosingMember 2022-01-01 2022-03-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-03-31 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-03-31 0000832101 2020-03-17 2020-03-17 0000832101 2015-12-01 2015-12-01 0000832101 2022-04-01 2022-04-30 0000832101 iex:EmployeesMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000832101 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000832101 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000832101 us-gaap:CostOfSalesMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000832101 us-gaap:CostOfSalesMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000832101 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000832101 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000832101 iex:AcceleratedStockRetireeEligibilityMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000832101 us-gaap:EmployeeStockOptionMember 2022-12-31 0000832101 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000832101 us-gaap:EmployeeStockOptionMember 2023-03-31 0000832101 iex:EmployeesandNonemployeeDirectorsMember us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0000832101 us-gaap:RestrictedStockMember 2022-12-31 0000832101 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0000832101 us-gaap:RestrictedStockMember 2023-03-31 0000832101 us-gaap:CostOfSalesMember us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0000832101 us-gaap:CostOfSalesMember us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0000832101 us-gaap:RestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0000832101 us-gaap:RestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0000832101 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0000832101 iex:CashsettledRestrictedStockMember 2023-01-01 2023-03-31 0000832101 iex:CashsettledRestrictedStockMember 2022-12-31 0000832101 iex:CashsettledRestrictedStockMember 2023-03-31 0000832101 iex:CashsettledRestrictedStockMember us-gaap:CostOfSalesMember 2023-01-01 2023-03-31 0000832101 iex:CashsettledRestrictedStockMember us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0000832101 iex:CashsettledRestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0000832101 iex:CashsettledRestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0000832101 iex:CashsettledRestrictedStockMember 2022-01-01 2022-03-31 0000832101 us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0000832101 us-gaap:PerformanceSharesMember 2022-01-01 2022-03-31 0000832101 us-gaap:PerformanceSharesMember 2022-12-31 0000832101 us-gaap:PerformanceSharesMember 2023-03-31 0000832101 us-gaap:PerformanceSharesMember 2023-01-31 2023-01-31 0000832101 us-gaap:PerformanceSharesMember 2023-02-01 2023-02-28 0000832101 us-gaap:PerformanceSharesMember us-gaap:CostOfSalesMember 2023-01-01 2023-03-31 0000832101 us-gaap:PerformanceSharesMember us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0000832101 us-gaap:PerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0000832101 us-gaap:PerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0000832101 us-gaap:PerformanceSharesMember iex:AcceleratedStockRetireeEligibilityMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0000832101 us-gaap:PensionPlansDefinedBenefitMember country:US 2023-01-01 2023-03-31 0000832101 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-03-31 0000832101 us-gaap:PensionPlansDefinedBenefitMember country:US 2022-01-01 2022-03-31 0000832101 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-03-31 0000832101 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-01 2023-03-31 0000832101 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-03-31 0000832101 us-gaap:PensionPlansDefinedBenefitMember 2023-03-31 0000832101 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-03-31 0000832101 us-gaap:SubsequentEventMember iex:IridianSpectralTechnologiesMember 2023-04-25 2023-04-25 iso4217:CAD 0000832101 iex:IridianSpectralTechnologiesMember iex:IridianSpectralTechnologiesMember 2022-01-01 2022-12-31
T a b l e o f C o n t e n t s

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________
Form 10-Q
☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2023
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number 1-10235
IDEX CORP ORATION
(Exact name of registrant as specified in its charter)
Delaware 36-3555336
(State or other jurisdiction of
incorporation or organization) 		(I.R.S. Employer
Identification No.)
3100 Sanders Road, Suite 301, Northbrook, Illinois 60062
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: ( 847 ) 498-7070
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $.01 per share IEX New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☑
Accelerated filer ☐
Non-accelerated filer ☐
Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☑
Number of shares of common stock of IDEX Corporation outstanding as of April 21, 2023: 75,576,366 .

T a b l e o f C o n t e n t s

TABLE OF CONTENTS
Item 1.
Item 2.
Item 3.
Item 4.
Item 1.
Item 1A.
Item 2.
Item 6.

T a b l e o f C o n t e n t s

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

IDEX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in millions, except per share amounts)
(unaudited)
March 31, 2023 December 31, 2022
ASSETS
Current assets
Cash and cash equivalents $ 510.7 $ 430.2
Receivables, less allowance for credit losses of $ 7.9 and $ 8.0 , respectively
446.5 442.8
Inventories 497.6 470.9
Other current assets 69.7 55.4
Total current assets 1,524.5 1,399.3
Property, plant and equipment, net of accumulated depreciation of $ 528.5 and $ 516.7 , respectively
397.0 382.1
Goodwill 2,657.9 2,638.1
Intangible assets - net 933.5 947.8
Other noncurrent assets 145.1 144.6
Total assets $ 5,658.0 $ 5,511.9
LIABILITIES AND EQUITY
Current liabilities
Trade accounts payable $ 216.0 $ 208.9
Accrued expenses 275.9 289.1
Dividends payable — 45.6
Total current liabilities 491.9 543.6
Long-term borrowings 1,470.7 1,468.7
Deferred income taxes 267.3 264.2
Other noncurrent liabilities 198.6 195.8
Total liabilities 2,428.5 2,472.3
Commitments and contingencies
Shareholders’ equity
Preferred stock:
Authorized: 5,000,000 shares, $ .01 per share par value; Issued: None
— —
Common stock:
Authorized: 150,000,000 shares, $ .01 per share par value
Issued: 90,069,559 shares at March 31, 2023 and 90,064,988 shares at December 31, 2022
0.9 0.9
Additional paid-in capital 830.0 817.2
Retained earnings 3,671.5 3,531.7
Treasury stock at cost: 14,386,036 shares at March 31, 2023 and 14,451,032 shares at December 31, 2022
( 1,184.0 ) ( 1,184.3 )
Accumulated other comprehensive loss ( 89.2 ) ( 126.2 )
Total shareholders’ equity 3,229.2 3,039.3
Noncontrolling interest 0.3 0.3
Total equity 3,229.5 3,039.6
Total liabilities and equity $ 5,658.0 $ 5,511.9
See Notes to Condensed Consolidated Financial Statements
1
T a b l e o f C o n t e n t s

IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In millions, except per share amounts)
(unaudited)

Three Months Ended March 31,
2023 2022
Net sales $ 845.4 $ 751.1
Cost of sales 462.9 408.6
Gross profit 382.5 342.5
Selling, general and administrative expenses 189.7 154.3
Restructuring expenses and asset impairments 0.5 0.6
Operating income 192.3 187.6
Other (income) expense - net ( 0.6 ) ( 2.3 )
Interest expense 13.1 9.5
Income before income taxes 179.8 180.4
Provision for income taxes 40.0 40.5
Net income 139.8 139.9
Net loss attributable to noncontrolling interest — 0.1
Net income attributable to IDEX $ 139.8 $ 140.0
Earnings per common share:
Basic earnings per common share attributable to IDEX $ 1.85 $ 1.84
Diluted earnings per common share attributable to IDEX $ 1.84 $ 1.83
Share data:
Basic weighted average common shares outstanding 75.6 76.1
Diluted weighted average common shares outstanding 75.9 76.4
See Notes to Condensed Consolidated Financial Statements
2
T a b l e o f C o n t e n t s

IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In millions)
(unaudited)
Three Months Ended March 31,
2023 2022
Net income $ 139.8 $ 139.9
Other comprehensive income (loss):
Pension and other postretirement adjustments, net of tax
0.4 0.6
Cumulative translation adjustment
36.6 ( 19.5 )
Other comprehensive income (loss) 37.0 ( 18.9 )
Comprehensive income 176.8 121.0
Comprehensive loss attributable to noncontrolling interest — —
Comprehensive income attributable to IDEX $ 176.8 $ 121.0
See Notes to Condensed Consolidated Financial Statements
3
T a b l e o f C o n t e n t s

IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(Dollars in millions)
(unaudited)

Accumulated Other Comprehensive Loss
Common
Stock and
Additional
Paid-In Capital 		Retained
Earnings 		Cumulative
Translation
Adjustment 		Retirement
Benefits
Adjustment 		Treasury
Stock 		Total
Shareholders’
Equity 		Noncontrolling Interest Total Equity
Balance, December 31, 2022 $ 818.1 $ 3,531.7 $ ( 137.1 ) $ 10.9 $ ( 1,184.3 ) $ 3,039.3 $ 0.3 $ 3,039.6
Net income — 139.8 — — — 139.8 — 139.8
Cumulative translation adjustment — — 36.6 — — 36.6 — 36.6
Net change in retirement obligations (net of tax of $ 0.2 )
— — — 0.4 — 0.4 — 0.4
Issuance of 84,666 shares of common stock from issuance of unvested shares, performance share units and exercise of stock options (net of tax of $ 1.8 )
— — — — 4.7 4.7 — 4.7
Shares surrendered for tax withholding — — — — ( 4.4 ) ( 4.4 ) — ( 4.4 )
Share-based compensation 12.8 — — — — 12.8 — 12.8
Balance, March 31, 2023 $ 830.9 $ 3,671.5 $ ( 100.5 ) $ 11.3 $ ( 1,184.0 ) $ 3,229.2 $ 0.3 $ 3,229.5


Accumulated Other Comprehensive Loss
Common
Stock and
Additional
Paid-In Capital 		Retained
Earnings 		Cumulative
Translation
Adjustment 		Retirement
Benefits
Adjustment 		Treasury
Stock 		Total
Shareholders’
Equity 		Noncontrolling Interest Total Equity
Balance, December 31, 2021 $ 796.5 $ 3,126.5 $ ( 62.2 ) $ ( 7.4 ) $ ( 1,050.3 ) $ 2,803.1 $ — $ 2,803.1
Net income (loss) — 140.0 — — — 140.0 ( 0.1 ) 139.9
Cumulative translation adjustment — — ( 19.5 ) — — ( 19.5 ) — ( 19.5 )
Net change in retirement obligations (net of tax of $ 0.2 )
— — — 0.6 — 0.6 — 0.6
Issuance of 73,755 shares of common stock from issuance of unvested shares, performance share units and exercise of stock options (net of tax of $ 1.7 )
— — — — 1.4 1.4 — 1.4
Repurchase of 147,500 shares of common stock
— — — — ( 28.3 ) ( 28.3 ) — ( 28.3 )
Shares surrendered for tax withholding — — — — ( 4.9 ) ( 4.9 ) — ( 4.9 )
Share-based compensation 6.6 — — — — 6.6 — 6.6
Balance, March 31, 2022 $ 803.1 $ 3,266.5 $ ( 81.7 ) $ ( 6.8 ) $ ( 1,082.1 ) $ 2,899.0 $ ( 0.1 ) $ 2,898.9

See Notes to Condensed Consolidated Financial Statements
4
T a b l e o f C o n t e n t s

IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
(unaudited)
Three Months Ended March 31,
2023 2022
Cash flows from operating activities
Net income $ 139.8 $ 139.9
Adjustments to reconcile net income to net cash provided by operating activities:
Gains on sales of assets ( 0.2 ) ( 2.7 )
Depreciation 12.8 12.2
Amortization of intangible assets 23.6 15.3
Amortization of debt issuance expenses 0.4 0.4
Share-based compensation expense 12.8 6.6
Deferred income taxes ( 0.2 ) 1.0
Changes in (net of the effect from acquisitions and foreign exchange):
Receivables ( 0.7 ) ( 49.0 )
Inventories ( 23.3 ) ( 50.2 )
Other current assets ( 11.1 ) ( 12.7 )
Trade accounts payable 7.6 28.1
Deferred revenue 10.2 6.4
Accrued expenses ( 24.9 ) ( 16.3 )
Other - net 1.1 0.7
Net cash flows provided by operating activities 147.9 79.7
Cash flows from investing activities
Purchases of property, plant and equipment ( 26.6 ) ( 16.1 )
Acquisition of businesses, net of cash acquired — ( 114.7 )
Proceeds from disposal of fixed assets 0.9 6.5
Purchase of marketable securities ( 3.2 ) —
Other - net ( 0.3 ) ( 0.1 )
Net cash flows used in investing activities ( 29.2 ) ( 124.4 )
Cash flows from financing activities
Dividends paid ( 45.5 ) ( 41.4 )
Proceeds from stock option exercises 4.7 1.4
Repurchases of common stock — ( 26.3 )
Shares surrendered for tax withholding ( 4.4 ) ( 4.9 )
Other - net — ( 0.1 )
Net cash flows used in financing activities ( 45.2 ) ( 71.3 )
Effect of exchange rate changes on cash and cash equivalents 7.0 ( 6.2 )
Net increase (decrease) in cash and cash equivalents 80.5 ( 122.2 )
Cash and cash equivalents at beginning of year 430.2 855.4
Cash and cash equivalents at end of period $ 510.7 $ 733.2
Supplemental cash flow information
Cash paid for:
Interest $ 4.1 $ 0.4
Income taxes 20.7 15.4

See Notes to Condensed Consolidated Financial Statements
5
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)

1. Basis of Presentation and Significant Accounting Policies

The Condensed Consolidated Financial Statements of IDEX Corporation (“IDEX” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) applicable to interim financial information and the instructions to Form 10-Q under the Securities Exchange Act of 1934, as amended. The statements are unaudited but include all adjustments, consisting only of recurring items, except as noted, that the Company considers necessary for a fair presentation of the information set forth herein. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the entire year.

The Condensed Consolidated Financial Statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in this report should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

Recently Adopted Accounting Standards

In October 2021, the Financial Accounting Standards Board issued Accounting Standards Update 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , which adds contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and requires that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with revenue recognition guidance. The Company adopted this standard on a prospective basis for the annual and interim periods beginning January 1, 2023. The adoption of this standard did not have a material impact on the Company’s Condensed Consolidated Financial Statements.

2. Acquisitions

All of the Company’s acquisitions of businesses have been accounted for under Accounting Standards Codification (“ASC”) 805, Business Combinations . Accordingly, the assets and liabilities of the acquired companies, after adjustments to reflect the fair values assigned to the assets and liabilities, have been included in the Company’s Condensed Consolidated Financial Statements from their respective dates of acquisition. The results of operations of Nexsight, LLC and its businesses Envirosight, WinCan, MyTana and Pipeline Renewal Technologies (“Nexsight”) (acquired February 28, 2022), KZ CO. (“KZValve”) (acquired May 2, 2022) and Muon B.V. and its subsidiaries (“Muon Group”) (acquired November 18, 2022) have been included in the Company’s Condensed Consolidated Financial Statements since the respective dates of acquisition. Supplemental pro forma information has not been provided as the acquisitions did not have a material impact on the Company’s Condensed Consolidated Financial Statements individually or in the aggregate.

2022 Acquisitions

Nexsight

On February 28, 2022, the Company acquired Nexsight in a partial stock and asset acquisition. Nexsight complements and creates synergies with the Company’s existing iPEK and ADS business units that design and create sewer crawlers, inspection and monitoring systems and software applications that allow teams to identify, anticipate and correct wastewater system issues remotely. Headquartered in Randolph, New Jersey, Nexsight operates in the Company’s Water reporting unit within the Fluid & Metering Technologies (“FMT”) segment. Nexsight was acquired for cash consideration of $ 112.5 million. The entire purchase price was funded with cash on hand. Goodwill and intangible assets recognized as part of this transaction were $ 54.7 million and $ 49.8 million, respectively. The goodwill is partially deductible for tax purposes.

The Company finalized the allocation of the purchase price for the Nexsight acquisition as of the acquisition date based on its understanding of the fair value of the acquired assets and assumed liabilities. These nonrecurring fair value measurements are classified as Level 3 in the fair value hierarchy.

The final allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows:

6
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Total
Current assets, net of cash acquired $ 16.6
Property, plant and equipment 2.0
Goodwill 54.7
Intangible assets 49.8
Other noncurrent assets 4.3
Total assets acquired 127.4
Current liabilities ( 9.2 )
Deferred income taxes ( 1.9 )
Other noncurrent liabilities ( 3.8 )
Net assets acquired
$ 112.5

Acquired intangible assets consist of trade names, customer relationships and software. The goodwill recorded for the acquisition reflects the strategic fit, revenue and earnings growth potential of this business.

The acquired intangible assets and weighted average amortization periods are as follows:
Total Weighted Average Life
Trade names $ 13.5 15
Customer relationships 31.5 10
Software 4.8 5
Acquired intangible assets $ 49.8

KZValve

On May 2, 2022, the Company acquired KZValve in an asset acquisition. KZValve is a leading manufacturer of electric valves and controllers used primarily in agricultural applications. KZValve augments and expands IDEX’s agricultural portfolio, complementing Banjo’s current fluid management solutions for these applications. Headquartered in Greenwood, Nebraska, KZValve operates in the Company’s Agriculture reporting unit within the FMT segment. KZValve was acquired for cash consideration of $ 120.1 million. The entire purchase was funded with cash on hand. Goodwill and intangible assets recognized as part of this transaction were $ 56.4 million and $ 52.0 million, respectively. The goodwill is deductible for tax purposes.

The Company made a preliminary allocation of the purchase price for the KZValve acquisition as of the acquisition date based on its understanding of the fair value of the acquired assets and assumed liabilities. These nonrecurring fair value measurements are classified as Level 3 in the fair value hierarchy. As the Company continues to obtain additional information about these assets and liabilities, and continues to integrate the newly acquired business, the Company will refine the estimates of fair value and more accurately allocate the purchase price. Only items identified as of the acquisition date are considered for subsequent adjustment. The Company will continue to make required adjustments to the purchase price allocation prior to the completion of the measurement period.

The preliminary allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows:

7
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Total
Current assets, net of cash acquired $ 9.7
Property, plant and equipment 1.8
Goodwill 56.4
Intangible assets 52.0
Deferred income taxes 0.2
Other noncurrent assets 1.0
Total assets acquired 121.1
Current liabilities ( 1.0 )
Net assets acquired
$ 120.1

Acquired intangible assets consist of trade names, customer relationships and unpatented technology. The goodwill recorded for the acquisition reflects the strategic fit, revenue and earnings growth potential of this business.

The acquired intangible assets and weighted average amortization periods are as follows:
Total Weighted Average Life
Trade names $ 7.5 15
Customer relationships 36.0 13
Unpatented technology 8.5 10
Acquired intangible assets $ 52.0

Muon Group

On November 18, 2022, the Company acquired the stock of Muon Group. Muon Group manufactures highly precise flowpaths in a variety of materials that enable the movement of various liquids and gases in critical applications for medical, semiconductor, food processing, digital printing and filtration technologies. Muon Group maintains operations in Hapert, the Netherlands; Eerbeek, the Netherlands; Wijchen, the Netherlands; Dorset, United Kingdom and Pune, India and operates in the Company’s Scientific Fluidics & Optics reporting unit within the Health & Science Technologies (“HST”) segment. Muon Group was acquired for cash consideration of $ 713.0 million. The purchase price was funded with $ 342.6 million of cash on hand, $ 170.4 million of proceeds from the Company's Revolving Credit Facility and $ 200.0 million of proceeds from the Company's Term Facility. Goodwill and intangible assets recognized as part of this transaction were $ 393.0 million and $ 319.1 million, respectively. The goodwill is not deductible for tax purposes.

The Company made a preliminary allocation of the purchase price for the Muon Group acquisition as of the acquisition date based on its understanding of the fair value of the acquired assets and assumed liabilities. These nonrecurring fair value measurements are classified as Level 3 in the fair value hierarchy. As the Company continues to obtain additional information about these assets and liabilities, including intangible asset appraisals, and continues to integrate the newly acquired business, the Company will refine the estimates of fair value and more accurately allocate the purchase price. Only items identified as of the acquisition date are considered for subsequent adjustment. The Company will continue to make required adjustments to the purchase price allocation prior to the completion of the measurement period.

The preliminary allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows:

8
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Total
Current assets, net of cash acquired $ 52.5
Property, plant and equipment 59.1
Goodwill 393.0
Intangible assets 319.1
Other noncurrent assets 9.6
Total assets acquired 833.3
Current liabilities ( 25.5 )
Deferred income taxes ( 83.9 )
Other noncurrent liabilities ( 10.9 )
Net assets acquired
$ 713.0

Acquired intangible assets consist of trade names, customer relationships and unpatented technology. The goodwill recorded for the acquisition reflects the strategic fit, revenue and earnings growth potential of this business.

The acquired intangible assets and weighted average amortization periods are as follows:
Total Weighted Average Life
Trade names $ 38.3 15
Customer relationships 212.4 13
Unpatented technology 68.4 11
Acquired intangible assets $ 319.1

The Company incurred $ 1.1 million and $ 0.9 million of acquisition-related costs during the three months ended March 31, 2023 and 2022, respectively. These costs were recorded in Selling, general and administrative expenses and were related to completed transactions, pending transactions and potential transactions, including transactions that ultimately were not completed.

3. Business Segments

IDEX has three reportable business segments: Fluid & Metering Technologies (“FMT”), Health & Science Technologies (“HST”) and Fire & Safety/Diversified Products (“FSDP”).

The FMT segment designs, produces and distributes positive displacement pumps, valves, small volume provers, flow meters, injectors and other fluid-handling pump modules and systems and provides flow monitoring and other services for the food, chemical, general industrial, water and wastewater, agriculture and energy industries. FMT application-specific pump and metering solutions serve a diverse range of end markets, including industrial infrastructure (fossil fuels, refined and alternative fuels and water and wastewater), energy, chemical processing, agriculture, food and beverage, semiconductor, pulp and paper, automotive/transportation, plastics and resins, electronics and electrical, construction and mining, pharmaceutical and biopharmaceutical, machinery and numerous other specialty niche markets.

The HST segment designs, produces and distributes a wide range of precision fluidics, rotary lobe pumps, centrifugal and positive displacement pumps, roll compaction and drying systems, micro-precision components, pneumatic components and sealing solutions, high performance molded and extruded sealing components, custom mechanical and shaft seals, engineered hygienic mixers and valves, biocompatible medical devices and implantables, air compressors and blowers, optical components and coatings, laboratory and commercial equipment, precision photonic solutions and precision gear and peristaltic pump technologies. HST serves a variety of end markets, including food and beverage, life sciences, analytical instruments, pharmaceutical and biopharmaceutical, industrial, semiconductor, digital printing, automotive/transportation, medical/dental, energy, cosmetics, marine, chemical, wastewater and water treatment, research and aerospace/defense markets.

9
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
The FSDP segment designs, produces and distributes firefighting pumps, valves and controls, rescue tools, lifting bags and other components and systems for the fire and rescue industry, engineered stainless steel banding and clamping devices used in a variety of industrial and commercial applications in the automotive, energy and industrial markets and precision equipment for dispensing, metering and mixing colorants and paints used in a variety of retail and commercial businesses in the paint and industrial markets around the world.

Information on the Company’s business segments is presented below based on the nature of the products and services offered. The Company uses Adjusted EBITDA as its principal measure of segment performance. Intersegment sales are accounted for at fair value as if the sales were to third parties.

Three Months Ended March 31,
2023 2022
Net sales
Fluid & Metering Technologies
External customers $ 321.1 $ 271.9
Intersegment sales 0.7 0.1
Total segment sales 321.8 272.0
Health & Science Technologies
External customers 350.3 314.6
Intersegment sales 0.7 0.6
Total segment sales 351.0 315.2
Fire & Safety/Diversified Products
External customers 174.0 164.6
Intersegment sales 0.4 0.1
Total segment sales 174.4 164.7
Intersegment eliminations ( 1.8 ) ( 0.8 )
Net sales $ 845.4 $ 751.1
ADJUSTED EBITDA
Fluid & Metering Technologies $ 106.2 $ 88.4
Health & Science Technologies 100.7 99.8
Fire & Safety/Diversified Products 49.7 44.4
Segment Adjusted EBITDA 256.6 232.6
Corporate and other ( 26.8 ) ( 17.9 )
Adjusted EBITDA 229.8 214.7
- Interest expense 13.1 9.5
- Depreciation 12.8 12.2
- Amortization 23.6 15.3
- Restructuring expenses and asset impairments 0.5 —
+ Gains on sales of asset — 2.7
Income before income taxes $ 179.8 $ 180.4

10
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
March 31,
2023 		December 31,
2022
ASSETS
Fluid & Metering Technologies $ 1,720.9 $ 1,676.9
Health & Science Technologies 2,960.9 2,931.1
Fire & Safety/Diversified Products 787.3 771.8
Corporate and other 188.9 132.1
Total assets $ 5,658.0 $ 5,511.9

4. Revenue

Disaggregation of Revenue

The Company has a comprehensive offering of products, including technologies, built to customers’ specifications that are sold in niche markets throughout the world. The Company disaggregates its revenue from contracts with customers by reporting unit and geographical region for each segment as the Company believes it best depicts how the amount, nature, timing and uncertainty of its revenue and cash flows are affected by economic factors. Revenue was attributed to geographical region based on the location of the customer. The following tables present revenue disaggregated by reporting unit and geographical region.

Revenue by reporting unit for the three months ended March 31, 2023 and 2022 was as follows:

Three Months Ended March 31,
2023 2022
Pumps $ 105.1 $ 97.4
Water 94.1 64.4
Energy 50.7 48.3
Agriculture 38.6 32.3
Valves 33.3 29.6
Intersegment elimination ( 0.7 ) ( 0.1 )
Fluid & Metering Technologies 321.1 271.9
Scientific Fluidics & Optics 178.6 141.2
Performance Pneumatic Technologies 69.4 62.0
Sealing Solutions 64.7 70.2
Material Processing Technologies 27.7 33.7
Micropump 10.6 8.1
Intersegment elimination ( 0.7 ) ( 0.6 )
Health & Science Technologies 350.3 314.6
Fire & Safety 106.2 95.7
Dispensing 36.2 41.6
BAND-IT 32.0 27.4
Intersegment elimination ( 0.4 ) ( 0.1 )
Fire & Safety/Diversified Products 174.0 164.6
Net sales $ 845.4 $ 751.1


11
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Revenue by geographical region for the three months ended March 31, 2023 and 2022 was as follows:

Three Months Ended March 31, 2023
FMT HST FSDP IDEX
U.S. $ 176.8 $ 149.6 $ 89.4 $ 415.8
North America, excluding U.S. 19.4 5.2 8.5 33.1
Europe 59.2 120.9 44.7 224.8
Asia 45.1 66.6 23.4 135.1
Other (1)
21.3 8.7 8.4 38.4
Intersegment elimination ( 0.7 ) ( 0.7 ) ( 0.4 ) ( 1.8 )
Net sales $ 321.1 $ 350.3 $ 174.0 $ 845.4

Three Months Ended March 31, 2022
FMT HST FSDP IDEX
U.S. $ 150.0 $ 152.0 $ 76.5 $ 378.5
North America, excluding U.S. 17.3 7.5 10.9 35.7
Europe 48.7 91.3 45.0 185.0
Asia 36.5 58.8 23.4 118.7
Other (1)
19.5 5.6 8.9 34.0
Intersegment elimination ( 0.1 ) ( 0.6 ) ( 0.1 ) ( 0.8 )
Net sales $ 271.9 $ 314.6 $ 164.6 $ 751.1

(1) Other includes: South America, Middle East, Australia and Africa.

Performance Obligations

The Company’s performance obligations are satisfied either at a point in time or over time as work progresses. Revenue from products and services transferred to customers at a point in time approximated 96 % of total revenues in both the three months ended March 31, 2023 and 2022. Revenue from products and services transferred to customers over time approximated 4 % of total revenues in both the three months ended March 31, 2023 and 2022.

Contract Balances

The timing of revenue recognition, billings and cash collections can result in customer receivables, advance payments or billings in excess of revenue recognized. Customer receivables include both amounts billed and currently due from customers as well as unbilled amounts (contract assets) and are included in Receivables on the Condensed Consolidated Balance Sheets. Amounts are billed in accordance with contractual terms or as work progresses. Unbilled amounts arise when the timing of billing differs from the timing of revenue recognized, such as when contract provisions require specific milestones to be met before a customer can be billed. Unbilled amounts primarily relate to performance obligations satisfied over time when the cost- to-cost method is utilized and the revenue recognized exceeds the amount billed to the customer as there is not yet a right to invoice in accordance with contractual terms. Unbilled amounts are recorded as a contract asset when the revenue associated with the contract is recognized prior to billing and derecognized when billed in accordance with the terms of the contract.







12
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
The composition of customer receivables was as follows:
March 31, 2023 December 31, 2022
Billed receivables $ 428.5 $ 421.3
Unbilled receivables 10.2 10.0
Total customer receivables $ 438.7 $ 431.3

Advance payments, deposits and billings in excess of revenue recognized are included in deferred revenue which is classified as current or noncurrent based on the timing of when the Company expects to recognize the revenue. The current portion is included in Accrued expenses and the noncurrent portion is included in Other noncurrent liabilities on the Condensed Consolidated Balance Sheets. Advance payments and deposits represent contract liabilities and are recorded when customers remit contractual cash payments in advance of the Company satisfying performance obligations under contractual arrangements, including those with performance obligations satisfied over time. The Company generally receives advance payments from customers related to maintenance services which are recognized ratably over the service term. The Company also receives deposits from customers on certain orders which the Company recognizes as revenue at a point in time. Billings in excess of revenue recognized represent contract liabilities and primarily relate to performance obligations satisfied over time when the cost-to-cost method is utilized and revenue cannot yet be recognized as the Company has not completed the corresponding performance obligation. Contract liabilities are derecognized when revenue is recognized and the performance obligation is satisfied.

The composition of deferred revenue was as follows:
March 31, 2023 December 31, 2022
Deferred revenue - current $ 55.4 $ 44.7
Deferred revenue - noncurrent 14.5 15.0
Total deferred revenue $ 69.9 $ 59.7

5. Earnings Per Common Share

Diluted earnings per common share (“EPS”) attributable to IDEX is computed by dividing Net income attributable to IDEX by the weighted average number of shares of common stock (basic) plus common stock equivalents (diluted) outstanding during the period. Common stock equivalents consist of stock options, which have been included in the calculation of weighted average shares outstanding using the treasury stock method, restricted stock and performance share units.

ASC 260, Earnings Per Share, concludes that all outstanding unvested share-based payment awards that contain rights to non-forfeitable dividends participate in undistributed earnings with common shareholders. If awards are considered participating securities, the Company is required to apply the two-class method of computing basic and diluted earnings per share. The Company has determined that its outstanding shares of restricted stock are participating securities. Accordingly, Diluted EPS attributable to IDEX was computed using the two-class method prescribed by ASC 260.

Basic weighted average shares outstanding reconciles to diluted weighted average shares outstanding as follows:

Three Months Ended March 31,
2023 2022
Basic weighted average common shares outstanding 75.6 76.1
Dilutive effect of stock options, restricted stock and performance share units 0.3 0.3
Diluted weighted average common shares outstanding 75.9 76.4

Options to purchase approximately 0.2 million and 0.5 million shares of common stock for the three months ended March 31, 2023 and 2022, respectively, were not included in the computation of Diluted EPS attributable to IDEX because the effect of their inclusion would have been antidilutive.
13
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)

6. Inventories

The components of inventories as of March 31, 2023 and December 31, 2022 were:
March 31,
2023 		December 31,
2022
Raw materials and component parts $ 303.8 $ 301.2
Work in process 54.9 54.3
Finished goods 138.9 115.4
Total inventories $ 497.6 $ 470.9

Inventories are stated at the lower of cost or net realizable value. Cost, which includes material, labor and overhead, is determined on a first in, first out basis.

7. Goodwill and Intangible Assets

The changes in the carrying amount of goodwill for the three months ended March 31, 2023, by reportable business segment, were as follows:

FMT HST FSDP IDEX
Goodwill $ 800.9 $ 1,644.8 $ 393.0 $ 2,838.7
Accumulated goodwill impairment losses ( 20.7 ) ( 149.8 ) ( 30.1 ) ( 200.6 )
Balance at January 1, 2023 780.2 1,495.0 362.9 2,638.1
Foreign currency translation 2.8 14.0 3.0 19.8
Acquisition adjustments ( 1.8 ) 1.8 — —
Balance at March 31, 2023 $ 781.2 $ 1,510.8 $ 365.9 $ 2,657.9

ASC 350, Goodwill and Other Intangible Assets, requires that goodwill be tested for impairment at the reporting unit level on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. In the first three months of 2023, there were no events or circumstances that would have required an interim impairment test. Annually, on October 31, goodwill and other acquired intangible assets with indefinite lives are tested for impairment. Based on the results of the Company’s annual impairment test at October 31, 2022, all reporting units had fair values in excess of their carrying values.

14
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
The following table provides the gross carrying value and accumulated amortization for each major class of intangible asset at March 31, 2023 and December 31, 2022:

At March 31, 2023 At December 31, 2022
Gross
Carrying
Amount 		Accumulated
Amortization 		Net Weighted
Average
Life 		Gross
Carrying
Amount 		Accumulated
Amortization 		Net
Amortized intangible assets:
Patents $ 2.9 $ ( 1.9 ) $ 1.0 12 $ 2.9 $ ( 1.8 ) $ 1.1
Trade names 188.4 ( 75.5 ) 112.9 15 186.5 ( 71.4 ) 115.1
Customer relationships 774.7 ( 196.6 ) 578.1 13 772.2 ( 184.9 ) 587.3
Unpatented technology 206.1 ( 59.3 ) 146.8 12 207.1 ( 57.8 ) 149.3
Software 4.9 ( 1.1 ) 3.8 5 4.8 ( 0.7 ) 4.1
Total amortized intangible assets 1,177.0 ( 334.4 ) 842.6 1,173.5 ( 316.6 ) 856.9
Indefinite-lived intangible assets:
Banjo trade name 62.1 — 62.1 62.1 — 62.1
Akron Brass trade name 28.8 — 28.8 28.8 — 28.8
Total intangible assets $ 1,267.9 $ ( 334.4 ) $ 933.5 $ 1,264.4 $ ( 316.6 ) $ 947.8

The Banjo trade name and the Akron Brass trade name are indefinite-lived intangible assets which are tested for impairment on an annual basis in accordance with ASC 350 or more frequently if events or changes in circumstances indicate that the assets might be impaired. Based on the results of the Company’s annual impairment test at October 31, 2022, these indefinite-lived intangible assets had fair values in excess of their carrying values. In the first three months of 2023, there were no events or circumstances that would have required an interim impairment test on these indefinite-lived intangible assets.

Amortization of intangible assets was $ 23.6 million and $ 15.3 million for the three months ended March 31, 2023 and 2022, respectively. Based on the intangible asset balances as of March 31, 2023, expected amortization expense for the remaining nine months of 2023 and for the years 2024 through 2027 is as follows:

Maturity of Intangible Assets Estimated Amortization
2023 (excluding the three months ended March 31, 2023) $ 68.8
2024 87.6
2025 86.2
2026 84.5
2027 80.5
15
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
8. Accrued Expenses

The components of accrued expenses as of March 31, 2023 and December 31, 2022 were:

March 31,
2023 		December 31,
2022
Payroll and related items $ 79.2 $ 102.7
Management incentive compensation 6.0 26.4
Income taxes payable 45.6 30.2
Insurance 11.0 11.2
Warranty 8.2 8.1
Deferred revenue 55.4 44.7
Lease liability 21.9 21.6
Restructuring 1.3 1.4
Accrued interest 14.0 5.5
Pension and retiree medical obligations 3.3 3.3
Other 30.0 34.0
Total accrued expenses $ 275.9 $ 289.1

9. Other Noncurrent Liabilities

The components of other noncurrent liabilities as of March 31, 2023 and December 31, 2022 were:

March 31,
2023 		December 31,
2022
Pension and retiree medical obligations $ 55.2 $ 55.1
Transition tax payable 9.1 9.1
Deferred revenue 14.5 15.0
Lease liability 99.3 96.6
Other 20.5 20.0
Total other noncurrent liabilities $ 198.6 $ 195.8


16
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
10. Borrowings

Borrowings at March 31, 2023 and December 31, 2022 consisted of the following:

March 31,
2023 		December 31,
2022
3.20 % Senior Notes, due June 2023 (1)
$ 100.0 $ 100.0
3.37 % Senior Notes, due June 2025
100.0 100.0
3.00 % Senior Notes, due May 2030
500.0 500.0
2.625 % Senior Notes, due June 2031
500.0 500.0
$ 800.0 million Revolving Credit Facility, due November 2027 (2)
79.4 77.7
$ 200.0 million Term Facility, due November 2027 (3)
200.0 200.0
Other borrowings 0.1 0.1
Total borrowings 1,479.5 1,477.8
Less current portion — —
Less deferred debt issuance costs 7.6 7.9
Less unaccreted debt discount 1.2 1.2
Long-term borrowings $ 1,470.7 $ 1,468.7

(1) As of March 31, 2023, the $ 100.0 million 3.20 % Senior Notes, due in June 2023, have not been classified as Short-term borrowings on the Condensed Consolidated Balance Sheets as the Company has the ability and intent to either refinance or repay these Notes using the available borrowing capacity of the Revolving Credit Facility, due November 2027. As a result, the 3.20 % Senior Notes remain classified as Long-term borrowings on the Condensed Consolidated Balance Sheets as of March 31, 2023.

(2) At March 31, 2023, there was $ 79.4 million outstanding under the Revolving Credit Facility with an interest rate of 3.32 % and $ 7.5 million of outstanding letters of credit, resulting in a net available borrowing capacity under the Revolving Credit Facility of approximately $ 713.1 million.

(3) The $ 200.0 million outstanding under the Term Facility bears an interest rate of 5.83 %.

At March 31, 2023, the Company was in compliance with covenants contained in the credit agreement associated with the Revolving Credit Facility as well as other long-term debt agreements.

11. Fair Value Measurements

ASC 820, Fair Value Measurements and Disclosures, defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow) and the cost approach (cost to replace the service capacity of an asset or replacement cost). The standard utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

• Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
• Level 2: Inputs, other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
• Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

17
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
The following table summarizes the basis used to measure the Company’s financial assets (liabilities) at fair value on a recurring basis in the balance sheets at March 31, 2023 and December 31, 2022:
Basis of Fair Value Measurements
Balance at March 31, 2023 Level 1 Level 2 Level 3
Trading securities - mutual funds held in nonqualified SERP (1)
$ 8.1 $ 8.1 $ — $ —
Available-for-sale securities - equities (2)
3.2 3.2 — —
Basis of Fair Value Measurements
Balance at December 31, 2022 Level 1 Level 2 Level 3
Trading securities - mutual funds held in nonqualified SERP (1)
$ 7.5 $ 7.5 $ — $ —

(1) The Supplemental Executive Retirement Plan (“SERP”) investment assets are offset by a SERP liability which represents the Company’s obligation to distribute SERP funds to participants.

(2) At March 31, 2023, the securities are included in Other current assets on the Company’s Condensed Consolidated Balance Sheets and are available for overnight cash settlement, if necessary, to fund current operations.

There were no transfers of assets or liabilities between Level 1 and Level 2 during the three months ended March 31, 2023 or the year ended December 31, 2022.

The carrying values of the Company’s cash and cash equivalents, accounts receivable, marketable securities, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. At March 31, 2023 and December 31, 2022, the fair value of the outstanding indebtedness described in Note 10 based on quoted market prices and current market rates for debt with similar credit risk and maturity was approximately $ 1,347.8 million and $ 1,328.7 million, respectively, compared to the carrying value of $ 1,478.3 million and $ 1,476.6 million, respectively. These fair value measurements are classified as Level 2 within the fair value hierarchy since they are determined based upon significant inputs observable in the market, including interest rates on recent financing transactions to entities with a credit rating similar to the Company’s rating.
18
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
12. Leases

The Company leases certain office facilities, warehouses, manufacturing plants, equipment (which includes both office and plant equipment) and vehicles under operating leases and certain plant equipment under financing leases. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term.

Certain leases include one or more options to renew. The exercise of lease renewal options is at the Company’s sole discretion. The Company does not include renewal periods in any of the leases’ terms until the renewal is executed as they are generally not reasonably certain of being exercised. The Company does not have any material purchase options.

Certain of the Company’s lease agreements have rental payments that are adjusted periodically for inflation or that are based on usage. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Supplemental balance sheet information related to leases as of March 31, 2023 and December 31, 2022 was as follows:

Balance Sheet Caption March 31, 2023 December 31, 2022
Right-of-Use (“ROU”) Assets:
Building ROU assets - net - operating Other noncurrent assets $ 108.3 $ 104.4
Equipment ROU assets - net - operating Other noncurrent assets 5.2 5.6
Equipment ROU assets - net - financing Property, plant and equipment 5.9 6.1
Total ROU assets - net $ 119.4 $ 116.1
Lease Liabilities:
Current lease liabilities Accrued expenses $ 21.9 $ 21.6
Noncurrent lease liabilities Other noncurrent liabilities 99.3 96.6
Total lease liabilities $ 121.2 $ 118.2

The components of lease cost for the three months ended March 31, 2023 and 2022 were as follows:

Three Months Ended March 31,
2023 2022
Fixed lease cost (1)
$ 8.2 $ 7.4
Variable lease cost 0.7 0.4
Total lease cost $ 8.9 $ 7.8

(1) Includes short-term leases, which are immaterial.

Supplemental cash flow information related to leases for the three months ended March 31, 2023 and 2022 was as follows:

Three Months Ended March 31,
2023 2022
Cash paid for amounts included in the measurement of lease liabilities $ 8.4 $ 7.4
Right-of-use assets obtained in exchange for new lease liabilities 9.0 8.3
19
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Other supplemental information related to leases as of March 31, 2023 and December 31, 2022 was as follows:

Lease Term and Discount Rate March 31, 2023 December 31, 2022
Weighted-average remaining lease term (years):
Operating leases - building and equipment 7.39 7.43
Operating leases - vehicles 2.20 2.14
Financing leases - equipment 2.26 2.05
Weighted-average discount rate:
Operating leases - building and equipment 3.56 % 3.41 %
Operating leases - vehicles 2.29 % 1.70 %
Financing leases - equipment 4.16 % 4.48 %

The Company uses its incremental borrowing rate to determine the present value of the lease payments.

Total lease liabilities at March 31, 2023 have scheduled maturities as follows:
Maturity of Lease Liabilities Operating Leases
2023 (excluding the three months ended March 31, 2023) $ 19.3
2024 19.7
2025 22.5
2026 17.8
2027 14.2
Thereafter 48.2
Total lease payments 141.7
Less: Imputed interest ( 20.5 )
Present value of lease liabilities $ 121.2

13. Restructuring Expenses and Asset Impairments

From time to time, the Company incurs costs to facilitate long-term sustainable growth through cost reduction actions, consisting of employee reductions, facility rationalization and contract termination costs. These costs include severance costs, exit costs and asset impairments and are included in Restructuring expenses and asset impairments in the Condensed Consolidated Statements of Income. Severance costs primarily consist of severance benefits through payroll continuation, COBRA subsidies, outplacement services, conditional separation costs and employer tax liabilities, while exit costs primarily consist of lease exit and contract termination costs.

2023 Initiative

During the three months ended March 31, 2023, the Company incurred severance costs related to employee reductions.

Pre-tax restructuring expenses and asset impairments by segment for the three months ended March 31, 2023 were as follows:

20
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Three Months Ended March 31, 2023
Severance Costs Exit Costs Asset Impairments Total
Fluid & Metering Technologies $ 0.1 $ — $ — $ 0.1
Health & Science Technologies 0.3 — — 0.3
Fire & Safety/Diversified Products 0.1 — — 0.1
Corporate/Other — — — —
Restructuring expenses and asset impairments $ 0.5 $ — $ — $ 0.5

2022 Initiative

During the three months ended March 31, 2022, the Company incurred severance costs related to employee reductions.

Pre-tax restructuring expenses and asset impairments by segment for the three months ended March 31, 2022 were as follows:

Three Months Ended March 31, 2022
Severance Costs Exit Costs Asset Impairments Total
Fluid & Metering Technologies $ 0.3 $ — $ — $ 0.3
Health & Science Technologies 0.1 — — 0.1
Fire & Safety/Diversified Products — — — —
Corporate/Other 0.2 — — 0.2
Restructuring expenses and asset impairments $ 0.6 $ — $ — $ 0.6

Restructuring accruals reflected in Accrued expenses in the Company’s Condensed Consolidated Balance Sheets are as follows:
Restructuring Initiatives
Balance at January 1, 2023 $ 1.4
Restructuring expenses 0.5
Payments, utilization and other ( 0.6 )
Balance at March 31, 2023 $ 1.3

21
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
14. Other Comprehensive Income (Loss)

The components of Other comprehensive income (loss) are as follows:

Three Months Ended March 31, 2023 Three Months Ended March 31, 2022
Pre-tax Tax Net of tax Pre-tax Tax Net of tax
Cumulative translation adjustment $ 36.6 $ — $ 36.6 $ ( 19.5 ) $ — $ ( 19.5 )
Pension and other postretirement adjustments 0.6 ( 0.2 ) 0.4 0.8 ( 0.2 ) 0.6
Total other comprehensive income (loss) $ 37.2 $ ( 0.2 ) $ 37.0 $ ( 18.7 ) $ ( 0.2 ) $ ( 18.9 )

The amounts reclassified from Accumulated other comprehensive loss to Net income during the three months ended March 31, 2023 and 2022 are as follows:

Three Months Ended March 31,
2023 2022 Income Statement Caption
Pension and other postretirement plans:
Amortization of service cost $ 0.6 $ 0.8 Other (income) expense - net
Total before tax 0.6 0.8
Provision for income taxes ( 0.2 ) ( 0.2 )
Total net of tax $ 0.4 $ 0.6

15. Share Repurchases

On March 17, 2020, the Company’s Board of Directors approved an increase of $ 500.0 million in the authorized level of repurchases of common stock. This approval is in addition to the prior repurchase authorization of the Board of Directors of $ 300.0 million on December 1, 2015. These authorizations have no expiration date. Repurchases under the program will be funded with future cash flow generation or borrowings available under the Revolving Credit Facility. There were no share repurchases during the three months ended March 31, 2023. During the three months ended March 31, 2022, the Company repurchased a total of 147,500 shares at a cost of $ 28.3 million, of which $ 2.0 million was settled in April 2022. As of March 31, 2023, the amount of share repurchase authorization remaining was $ 563.8 million.

16. Share-Based Compensation

The Company typically grants equity awards annually at its regularly scheduled first quarter meeting of the Board of Directors based on the recommendation from the Compensation Committee.

The Company’s policy is to recognize compensation cost on a straight-line basis, assuming forfeitures, over the requisite service period for the entire award. Classification of stock compensation cost within the Condensed Consolidated Statements of Income is consistent with the classification of cash compensation for the same employees.

Stock Options

Stock options granted under the Company’s plans are generally non-qualified and are granted with an exercise price equal to the market price of the Company’s stock on the date of grant. The fair value of each option grant was estimated on the date of the grant using the Black Scholes valuation model. Stock options generally vest ratably over four years , with vesting beginning one year from the date of grant, and generally expire 10 years from the date of grant. The service period for certain retiree eligible participants is accelerated.

22
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Three Months Ended March 31,
2023 2022
Weighted average fair value of grants $ 60.80 $ 41.66
Dividend yield 1.06 % 1.14 %
Volatility 27.19 % 25.15 %
Risk-free interest rate 4.12 %
1.83 %
Expected life (in years) 4.50 4.90

Total compensation cost for stock options is recorded in the Condensed Consolidated Statements of Income as follows:

Three Months Ended March 31,
2023 2022
Cost of goods sold $ 0.3 $ 0.3
Selling, general and administrative expenses (1)
5.7 3.1
Total expense before income taxes 6.0 3.4
Income tax benefit ( 0.4 ) ( 0.3 )
Total expense after income taxes $ 5.6 $ 3.1

(1) The three months ended March 31, 2023 includes an additional $ 2.4 million of accelerated stock compensation costs for retiree eligible participants as compared with the same period in 2022.

A summary of the Company’s stock option activity as of March 31, 2023 and changes during the three months ended March 31, 2023 are presented in the following table:
Stock Options Shares Weighted
Average
Price 		Weighted-Average
Remaining
Contractual Term 		Aggregate
Intrinsic
Value
(Dollars in millions except weighted average price)
Outstanding at January 1, 2023 1,015,572 $ 161.45 6.94 $ 67.9
Granted 208,305 225.71
Exercised ( 33,460 ) 141.19
Forfeited ( 8,491 ) 196.25
Outstanding at March 31, 2023 1,181,926 $ 173.10 7.28 $ 68.5
Vested and expected to vest as of March 31, 2023 1,130,292 $ 171.52 7.20 $ 67.3
Exercisable at March 31, 2023 639,677 $ 146.97 5.88 $ 53.8

As of March 31, 2023, there was $ 13.8 million of total unrecognized compensation cost related to stock options that is expected to be recognized over a weighted-average period of 1.6 years.

Restricted Stock

Restricted stock awards generally cliff vest after three years for employees and non-employee directors. The service period for certain retiree eligible participants is accelerated. Unvested restricted stock carries dividend and voting rights and the sale of the shares is restricted prior to the date of vesting. Dividends are paid on restricted stock awards and their fair value is equal to the market price of the Company’s stock at the date of the grant. A summary of the Company’s restricted stock activity as of March 31, 2023 and changes during the three months ended March 31, 2023 are presented in the following table:

23
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Restricted Stock Shares Weighted-Average
Grant Date Fair
Value
Unvested at January 1, 2023 104,382 $ 179.45
Granted 25,595 225.73
Vested ( 16,905 ) 171.67
Forfeited ( 3,430 ) 204.03
Unvested at March 31, 2023 109,642 $ 190.69

Total compensation cost for restricted stock is recorded in the Condensed Consolidated Statements of Income as follows:

Three Months Ended March 31,
2023 2022
Cost of goods sold $ 0.2 $ 0.2
Selling, general and administrative expenses 1.4 1.6
Total expense before income taxes 1.6 1.8
Income tax benefit ( 0.3 ) ( 0.4 )
Total expense after income taxes $ 1.3 $ 1.4

As of March 31, 2023, there was $ 9.9 million of total unrecognized compensation cost related to restricted stock that is expected to be recognized over a weighted-average period of 1.1 years.

Cash-Settled Restricted Stock

The Company also maintains a cash-settled share-based compensation plan for certain employees. Cash-settled restricted stock awards generally cliff vest after three years . The service period for certain retiree eligible participants is accelerated. Cash-settled restricted stock awards are recorded at fair value on a quarterly basis using the market price of the Company’s stock on the last day of the quarter. Dividend equivalents are paid on certain cash-settled restricted stock awards. A summary of the Company’s unvested cash-settled restricted stock activity as of March 31, 2023 and changes during the three months ended March 31, 2023 are presented in the following table:

Cash-Settled Restricted Stock Shares Weighted-Average
Fair Value
Unvested at January 1, 2023 57,356 $ 228.33
Granted 19,755 225.66
Vested ( 14,300 ) 230.78
Forfeited ( 1,265 ) 231.03
Unvested at March 31, 2023 61,546 $ 231.03

24
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Total compensation cost for cash-settled restricted stock is recorded in the Condensed Consolidated Statements of Income as follows:
Three Months Ended March 31,
2023 2022
Cost of goods sold $ 0.1 $ ( 0.1 )
Selling, general and administrative expenses 1.0 0.5
Total expense before income taxes 1.1 0.4
Income tax benefit — —
Total expense after income taxes $ 1.1 $ 0.4

As of March 31, 2023, there was $ 7.0 million of total unrecognized compensation cost related to cash-settled restricted shares that is expected to be recognized over a weighted-average period of 1.2 years.

Performance Share Units

Weighted average performance share unit fair values and assumptions for the period specified are disclosed below. The performance share units are market condition awards and have been assessed at fair value on the date of grant using a Monte Carlo simulation model.
Three Months Ended March 31,
2023 2022
Weighted average fair value of grants $ 308.18 $ 235.54
Dividend yield — % — %
Volatility 27.00 % 28.09 %
Risk-free interest rate 4.37 % 1.73 %
Expected life (in years) 2.94 2.93

A summary of the Company’s performance share unit activity as of March 31, 2023 and changes during the three months ended March 31, 2023 are presented in the following table:
Performance Share Units Shares Weighted-Average
Grant Date Fair
Value
Unvested at January 1, 2023 70,915 $ 236.66
Granted 28,030 308.18
Vested ( 18,105 ) 226.86
Forfeited ( 1,725 ) 261.13
Unvested at March 31, 2023 79,115 $ 264.89

On January 31, 2023, 18,105 performance share units vested. Based on the Company’s relative total shareholder return rank during the three year period ended January 31, 2023, the Company achieved a 173 % payout factor and issued 31,334 common shares in February 2023 for awards that vested in 2023.

25
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Total compensation cost for performance share units is recorded in the Condensed Consolidated Statements of Income as follows:
Three Months Ended March 31,
2023 2022
Cost of goods sold $ — $ —
Selling, general and administrative expenses (1)
5.2 1.3
Total expense before income taxes 5.2 1.3
Income tax benefit ( 0.1 ) ( 0.1 )
Total expense after income taxes $ 5.1 $ 1.2

(1) The three months ended March 31, 2023 includes an additional $ 3.4 million of accelerated stock compensation costs for retiree eligible participants as compared with the same period in 2022.

As of March 31, 2023, there was $ 5.7 million of total unrecognized compensation cost related to performance share units that is expected to be recognized over a weighted-average period of 1.2 years.

17. Retirement Benefits

The Company sponsors several qualified and nonqualified defined benefit and defined contribution pension plans as well as other post-retirement plans for its employees. The following tables provide the components of net periodic benefit cost for its major defined benefit plans and its other postretirement plans.
Pension Benefits
Three Months Ended March 31,
2023 2022
U.S. Non-U.S. U.S. Non-U.S.
Service cost $ — $ 0.3 $ — $ 0.5
Interest cost 0.1 0.7 0.1 0.2
Expected return on plan assets ( 0.1 ) ( 0.4 ) ( 0.1 ) ( 0.3 )
Net amortization 0.1 ( 0.2 ) 0.1 0.2
Net periodic cost $ 0.1 $ 0.4 $ 0.1 $ 0.6

Other Postretirement Benefits
Three Months Ended March 31,
2023 2022
Service cost $ 0.1 $ 0.2
Interest cost 0.2 0.1
Net amortization ( 0.2 ) ( 0.1 )
Net periodic cost $ 0.1 $ 0.2

The Company expects to contribute approximately $ 3.9 million to its defined benefit plans and $ 1.1 million to its other post-retirement benefit plans in 2023. During the first three months of 2023, the Company contributed a total of $ 1.3 million to fund these plans.

26
T a b l e o f C o n t e n t s

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
18. Legal Proceedings

The Company and certain of its subsidiaries are involved in pending and threatened legal, regulatory and other proceedings arising in the ordinary course of business. These proceedings may pertain to matters such as product liability or contract disputes, and may also involve governmental inquiries, inspections, audits or investigations relating to issues such as tax matters, intellectual property, environmental, health and safety issues, governmental regulations, employment and other matters. Although the results of such legal proceedings cannot be predicted with certainty, the Company believes that the ultimate disposition of these matters will not have a material adverse effect, individually or in the aggregate, on the Company’s business, financial condition, results of operations or cash flows.

19. Income Taxes

The Company’s provision for income taxes is based upon estimated annual tax rates for the year applied to federal, state and foreign income. The provision for income taxes decreased to $ 40.0 million for the three months ended March 31, 2023 from $ 40.5 million during the same period in 2022. The effective tax rate of 22.2 % for the three months ended March 31, 2023 was relatively consistent with 22.4 % during the same period in 2022.

20. Subsequent Events

On April 25, 2023, the Company entered into a definitive agreement to acquire Iridian Spectral Technologies ("Iridian") for cash consideration of 150.0 million Canadian dollars, subject to customary post-closing adjustments. With annual sales of 34 million Canadian dollars in 2022, Iridian is a leader in custom optical filter solutions serving the space, life science and telecommunications markets. Iridian complements and expands upon the solutions provided by our Scientific Fluidics & Optics businesses within the HST segment. The Company expects to close the transaction by the end of the second quarter of 2023, subject to customary closing conditions.






27
T a b l e o f C o n t e n t s
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with the Company’s Condensed Consolidated Financial Statements and related notes in this quarterly report. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. The Company’s actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under Item 1A, “Risk Factors” in the Company’s most recent annual report on Form 10-K and under the heading “Cautionary Statement Under the Private Securities Litigation Reform Act” discussed elsewhere in this quarterly report.

This discussion also includes certain non-GAAP financial measures that have been defined and reconciled to their most directly comparable measures that are in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) later in this Item under the headings “Non-GAAP Disclosures” and “Free Cash Flow.” This discussion also includes Operating working capital, which has been defined later in this Item under the heading “Liquidity and Capital Resources.” The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures prepared in accordance with U.S. GAAP. The financial results prepared in accordance with U.S. GAAP and the reconciliations from these results should be carefully evaluated.

Overview

IDEX is an applied solutions company specializing in the manufacture of fluid and metering technologies, health and science technologies and fire, safety and other diversified products built to customers’ specifications. IDEX’s products are sold in niche markets across a wide range of industries throughout the world. Accordingly, IDEX’s businesses are affected by levels of industrial activity and economic conditions in the U.S. and in other countries where it does business and by the relationship of the U.S. dollar to other currencies. Levels of capacity utilization and capital spending in certain industries and overall industrial activity are important factors that influence the demand for IDEX’s products.

Select key financial results for the three months ended March 31, 2023 when compared to the same period in the prior year are as follows:

• Sales of $845.4 million increased 13%; organic sales were up 6%.
• Net income of $139.8 million was flat; Net income margin of 16.5% decreased 210 basis points.
• Dilute d EPS attributable to IDEX o f $1.84 increased $0.01, or 1%; Adjusted diluted EPS attributable to IDEX o f $2.09 increased $0.13, or 7%.
• Adjusted EBITDA of $229.8 million increased 7%; Adjusted EBITDA margin of 27.2% decreased 140 basis points .
• Cash flows provided by operating activities of $147.9 million were up 86% due to lower investments in working capital in 2023 as compared with 2022. Free cash flow included higher capital expenditures and was $121.3 million, up 91%, and constituted 76% of adjusted net income attributable to IDEX.

28
T a b l e o f C o n t e n t s
Results of Operations
The following is a discussion and analysis of the Company’s results of operations for the three months ended March 31, 2023 compared with the three months ended March 31, 2022.

Three Months Ended March 31, Change
(Dollars in millions, except per share amounts) 2023 2022 $ % / bps
Net sales $ 845.4 $ 751.1 $ 94.3 13 %
Cost of sales 462.9 408.6 54.3 13 %
Gross profit 382.5 342.5 40.0 12 %
Gross margin 45.2 % 45.6 % n/a (40) bps
Selling, general and administrative expenses 189.7 154.3 35.4 23 %
Restructuring expenses and asset impairments 0.5 0.6 (0.1) (17 %)
Operating income 192.3 187.6 4.7 3 %
Other (income) expense - net (0.6) (2.3) 1.7 (74 %)
Interest expense 13.1 9.5 3.6 38 %
Income before income taxes 179.8 180.4 (0.6) — %
Provision for income taxes 40.0 40.5 (0.5) (1 %)
Effective tax rate 22.2 % 22.4 % n/a (20) bps
Net income attributable to IDEX $ 139.8 $ 140.0 $ (0.2) — %
Diluted earnings per common share attributable to IDEX $ 1.84 $ 1.83 $ 0.01 1 %

Net Sales

Sales for the three months ended March 31, 2023 increased 13% , reflecting a 6% increase in organic sales, a 9% increase from acquisitions (Muon Group - November 2022, KZValve - May 2022 and Nexsight - February 2022) net of divestitures (Knight - September 2022) and a 2% unfavorable impact from foreign currency translation. Sales increased 10% domestically and 15% internationally, and sales to customers outside the U.S. were approximately 51% of total sales in the first quarter of 2023 compared with 50% during the same period in 2022.

Cost of Sales

Cost of sales for the three months ended March 31, 2023 increased due to acquisitions, net of divestitures, inflation, higher sales volume and employee-related costs and unfavorable mix, partially offset by a favorable impact from foreign currency translation.

Gross Profit and Gross Margin

Gross profit and Gross margin were both positively impacted by favorable productivity and price/cost, partially offset by unfavorable mix, largely centered in HST, and employee-related inflation. While acquisitions also positively impacted Gross profit, they resulted in a dilutive impact to overall Gross margin.

Selling, General and Administrative Expenses

Selling, general and administrative expenses increased primarily due to the impact from acquisitions, including amortization, increases in employee-related costs, which includes an additional $5.8 million of accelerated stock compensation costs for retiree eligible participants, and higher discretionary spending both as compared with the same period in 2022.

Other (Income) Expense - Net

Other (income) expense - net was $0.6 million of income in the first quarter of 2023 compared to $2.3 million of income during the same period in 2022. The decrease was primarily due to $2.5 million of lower gains on the sale of assets and $1.7 million of higher foreign currency transaction losses as compared to the prior year period, partially offset by $1.6 million of gains on trading securities and $0.6 million of higher interest income in the current year period.
29
T a b l e o f C o n t e n t s

Interest Expense

Interest expense for the three months ended March 31, 2023 increased compared to the same period in 2022 due to the borrowings incurred under the Revolving Credit Facility and the Term Facility in connection with the Muon Group acquisition in November 2022.

Income Taxes

The Company’s provision for income taxes is based upon estimated annual tax rates for the year applied to federal, state and foreign income. The provision for income taxes decreased to $40.0 million for the three months ended March 31, 2023 from $40.5 million during the same period in 2022. The effective tax rate of 22.2% for the three months ended March 31, 2023 was relatively consistent with the effective tax rate of 22.4% during the same period in 2022.

Results of Reportable Business Segments

The Company has three reportable segments: Fluid & Metering Technologies (“FMT”), Health & Science Technologies (“HST”) and Fire & Safety/Diversified Products (“FSDP”). For a detailed description of the operations within each segment, refer to Note 3 in the Notes to Condensed Consolidated Financial Statements .

Within its three reportable segments, the Company maintains 13 reporting units where the Company focuses on organic growth and strategic acquisitions. Management’s primary measurements of segment performance are sales, adjusted earnings before interest, income taxes, depreciation and amortization (“Adjusted EBITDA”) and Adjusted EBITDA margin.

FMT HST FSDP
Pumps Scientific Fluidics & Optics Fire & Safety
Water Sealing Solutions Dispensing
Energy Performance Pneumatic Technologies BAND-IT
Valves Material Processing Technologies
Agriculture Micropump

The table below illustrates the percentages of the share of Net sales and Adjusted EBITDA contributed by each segment on the basis of total segments (not total Company) for the three months ended March 31, 2023.

Three Months Ended March 31, 2023
FMT HST FSDP IDEX
Net Sales 38 % 41 % 21 % 100 %
Adjusted EBITDA (1)
42 % 39 % 19 % 100 %

(1) Segment Adjusted EBITDA excludes the impact of unallocated corporate costs of $26.8 million for the three months ended March 31, 2023.













30
T a b l e o f C o n t e n t s
Fluid & Metering Technologies Segment

Three Months Ended March 31, Components of Change
(Dollars in millions) 2023 2022 Change Organic
Acq/Div (1)
Foreign Currency Total
Net sales $ 321.8 $ 272.0 18% 9% 11% (2%) 18%
Adjusted EBITDA 106.2 88.4 20% 14% 8% (2%) 20%
Adjusted EBITDA margin 33.0 % 32.5 % 50 bps 150 bps (100) bps — 50 bps

(1) Acquisitions included KZValve in May 2022 and Nexsight in February 2022. Divestitures included Knight in September 2022.

• Sales increased 18% domestically and 19% internationally. Sales to customers outside the U.S. were approximately 45% of total segment sales in both the first quarter of 2023 and the same period in 2022.
• The change in organic sales was attributed to increases in the following:
◦ Pumps reporting unit due to price capture and steady demand in the industrial market;
◦ Water reporting unit due to strength in the municipal water market, price capture and backlog execution;
◦ Valves reporting unit due to strong demand in China and the Middle East; and
◦ Energy reporting unit due to favorable demand in the mobile fuel markets as well as price capture.
These increases were partially offset by a decrease in the Agriculture reporting unit due to higher distribution inventory levels and bad weather delaying the planting season.
• Adjusted EBITDA margin of 33.0% increased 50 basis points compared with 32.5% during the same period in 2022. The change in Adjusted EBITDA margin was attributed to the following:
◦ Organic Adjusted EBITDA margin increased 150 basis points due to strong price/cost, favorable productivity and higher volume leverage, partially offset by increases in employee-related costs and discretionary spending.
◦ Acquisitions negatively impacted Adjusted EBITDA margin by 100 basis points due to the dilutive impact of acquisitions on overall FMT Adjusted EBITDA margin.

Health & Science Technologies Segment

Three Months Ended March 31, Components of Change
(Dollars in millions) 2023 2022 Change Organic
Acq/Div (1)
Foreign Currency Total
Net sales $ 351.0 $ 315.2 11% 3% 11% (3%) 11%
Adjusted EBITDA 100.7 99.8 1% (7%) 10% (2%) 1%
Adjusted EBITDA margin 28.7 % 31.7 % (300) bps (330) bps 20 bps 10 bps (300) bps

(1) Acquisitions included Muon Group in November 2022.

• Sales decreased 2% domestically and increased 23% internationally. Sales to customers outside the U.S. were approximately 57% of total segment sales in the first quarter of 2023 compared with 52% during the same period in 2022.
• The change in organic sales was attributed to increases in the following:
◦ Performance Pneumatics Technologies reporting unit due to strong targeted growth performance tied to fuel cells and increased China ventilator sales; and
◦ Scientific Fluidics & Optics reporting unit due to strong Next Gen Sequencing instrument demand, satellite broadband targeted growth initiatives and price capture, partially offset by lower demand from Analytical Instrumentation and Life Science original equipment manufacturers due to customer inventory recalibration, softness in the semiconductor market and the non-repeat of revenues from a COVID-19 testing application in the prior year.
These increases were partially offset by decreases in the following:
◦ Sealing Solutions reporting unit due to softness in the semiconductor market, partially offset by favorable demand in the automotive, mining and defense markets; and
◦ Material Processing Technologies reporting unit due to customer-driven project delays in the pharma and food/nutrition markets.
31
T a b l e o f C o n t e n t s

• Adjusted EBITDA margin of 28.7% decreased 300 basis points compared with 31.7% during the same period in 2022. The change in Adjusted EBITDA margin was attributed to the following:
◦ Organic Adjusted EBITDA margin decreased 330 basis points due to increases in employee-related costs, unfavorable mix and lower volume leverage, partially offset by favorable price/cost.
◦ Acquisitions positively impacted Adjusted EBITDA margin by 20 basis points due to the accretive impact of Muon Group on overall HST Adjusted EBITDA margin.
◦ Foreign currency positively impacted Adjusted EBITDA margin by 10 basis points.

Fire & Safety/Diversified Products Segment

Three Months Ended March 31, Components of Change
(Dollars in millions) 2023 2022 Change Organic Acq/Div Foreign Currency Total
Net sales $ 174.4 $ 164.7 6% 9% — (3%) 6%
Adjusted EBITDA 49.7 44.4 12% 15% — (3%) 12%
Adjusted EBITDA margin 28.5 % 26.9 % 160 bps 170 bps — (10) bps 160 bps

• Sales increased 17% domestically and decreased 4% internationally. Sales to customers outside the U.S. were approximately 49% of total segment sales in the first quarter of 2023 compared with 54% during the same period in 2022.
• The change in organic sales was attributed to increases in the following:
◦ Fire & Safety reporting unit due to strong execution, price realization, share gain with Fire original equipment manufacturers and continued demand for rescue tools; and
◦ BAND-IT reporting unit due to continued share gain in the automotive market as well as strong demand in the aerospace, industrial and energy markets.
These increases were partially offset by a decrease in the Dispensing reporting unit due to timing of projects in the Americas and Asia.
• Adjusted EBITDA margin of 28.5% increased 160 basis points compared with 26.9% in 2022. The change in Adjusted EBITDA margin was attributed to the following:
◦ Organic Adjusted EBITDA margin increased 170 basis points due to strong productivity, higher volume leverage and favorable price/cost, partially offset by increases in discretionary spending and employee-related costs as well as unfavorable mix.
◦ Foreign currency negatively impacted Adjusted EBITDA margin by 10 basis points.

32
T a b l e o f C o n t e n t s
Liquidity and Capital Resources

Liquidity

Based on management’s current expectations and currently available information, the Company believes current cash, cash from operations and cash available under the Revolving Credit Facility will be sufficient to meet its operating cash requirements, planned capital expenditures, interest and principal payments on all borrowings, pension and postretirement funding requirements, share repurchases and quarterly dividend payments to holders of the Company’s common stock for the foreseeable future. Additionally, in the event that suitable businesses are available for acquisition upon acceptable terms, the Company may obtain all or a portion of the financing for these acquisitions through the incurrence of additional borrowings.

At March 31, 2023, working capital was $1,032.6 million and the Company’s current ratio was 3.1 to 1. At March 31, 2023, the Company’s cash and cash equivalents totaled $510.7 million, of which $392.7 million was held outside of the United States. At March 31, 2023, there was $79.4 million outstanding under the Revolving Credit Facility and $7.5 million of outstanding letters of credit, resulting in a net available borrowing capacity under the Revolving Credit Facility of $713.1 million. In addition, there was $200.0 million outstanding under the Term Facility. The Company believes that additional borrowings through various financing alternatives remain available, if required.

Operating Working Capital

Operating working capital, calculated as Receivables plus Inventories minus Trade accounts payable, is used by management as a measurement of operational results as well as the short-term liquidity of the Company. The following table details operating working capital as of March 31, 2023 and December 31, 2022:

(In millions) March 31, 2023 December 31, 2022
Receivables $ 446.5 $ 442.8
Inventories 497.6 470.9
Less: Trade accounts payable (216.0) (208.9)
Operating working capital $ 728.1 $ 704.8

Operating working capital increased $23.3 million to $728.1 million during the three months ended March 31, 2023. Acquisitions and foreign currency translation contributed $6.9 million to the increase in operating working capital. Excluding those items, Receivables increased $0.6 million as a result of higher volume and price capture; Inventories increased $27.0 million to support planned production; and Trade accounts payable increased $11.2 million due to higher inventory purchases.

Cash Flow Summary

The following table is derived from the Condensed Consolidated Statements of Cash Flows:

Three Months Ended March 31,
(In millions) 2023 2022
Net cash flows provided by (used in):
Operating activities $ 147.9 $ 79.7
Investing activities (29.2) (124.4)
Financing activities (45.2) (71.3)

Operating Activities

Cash flows provided by operating activities increased $68.2 million to $147.9 million in the three months ended March 31, 2023 primarily due to lower investments in working capital in 2023 as compared with 2022.
33
T a b l e o f C o n t e n t s
Investing Activities

Cash flows used in investing activities decreased $95.2 million to $29.2 million in the three months ended March 31, 2023. The change is primarily due to the purchase of Nexsight in 2022, partially offset by higher capital expenditures in the first quarter of 2023.

Financing Activities

Cash flows used in financing activities decreased $26.1 million to $45.2 million in the three months ended March 31, 2023 from $71.3 million in the prior year period. The change is primarily due to the repurchase of 147,500 shares at a cost of $28.3 million in the first quarter of 2022, of which $2.0 million did not settle until April 2022.

Free Cash Flow

The Company believes free cash flow, a non-GAAP measure, is an important measure of performance because it provides a measurement of cash generated from operations that is available for payment obligations such as operating cash requirements, planned capital expenditures, interest and principal payments on all borrowings, pension and postretirement funding requirements and quarterly dividend payments to holders of the Company’s common stock as well as for funding acquisitions and share repurchases. Free cash flow is calculated as cash flows provided by operating activities less capital expenditures.

The following table reconciles free cash flow to cash flows provided by operating activities:

Three Months Ended March 31,
(Dollars in millions) 2023 2022
Cash flows provided by operating activities $ 147.9 $ 79.7
Less: capital expenditures (26.6) (16.1)
Free cash flow $ 121.3 $ 63.6
Free cash flow as a percent of adjusted net income attributable to IDEX 76.5 % 42.5 %

The increase in free cash flow as compared to 2022 is due to lower investments in working capital in 2023 as compared with 2022, partially offset by higher capital expenditures.

Cash Requirements

Pending Acquisitions

On April 25, 2023, the Company entered into a definitive agreement to acquire Iridian Spectral Technologies for cash consideration of 150.0 million Canadian dollars. The Company expects to close the transaction by the end of the second quarter of 2023, subject to customary closing conditions. Refer to Note 20 for further details.

Capital Expenditures

Capital expenditures generally include machinery and equipment that support growth and improved productivity, tooling, business system technology, replacement of equipment and investments in new facilities. The Company believes it has sufficient operating cash flows to continue to meet current obligations and invest in planned capital expenditures. Cash flows from operations were more than adequate to fund capital expenditures of $26.6 million and $16.1 million in the first three months of 2023 and 2022, respectively .

Debt Repayment

As of March 31, 2023, the Company has $100.0 million of 3.20% Senior Notes due June 2023. The Company expects to either refinance or repay the Notes using the available borrowing capacity of the Revolving Credit Facility, due November 2027.
34
T a b l e o f C o n t e n t s
Share Repurchases

There were no share repurchases during the three months ended March 31, 2023. As of March 31, 2023, the amount of share repurchase authorization remaining was $563.8 million . For additional information regarding the Company’s share repurchase program, refer to Note 15 in the Notes to Condensed Consolidated Financial Statements.

Dividends

Total dividend payments to common shareholders were $45.5 million during the three months ended March 31, 2023 compared with $41.4 million during the three months ended March 31, 2022.

Covenants

The key financial covenants that the Company is required to maintain in connection with the Revolving Credit Facility, the Term Facility, the 3.20% Senior Notes and the 3.37% Senior Notes, are a minimum interest coverage ratio of 3.0 to 1 and a maximum leverage ratio of 3.50 to 1. At March 31, 2023, the Company was in compliance with these financial covenants, as the Company’s interest coverage ratio was 22.48 to 1 for covenant calculation purposes and the leverage ratio was 1.55 to 1. There are no financial covenants relating to the 2.625% Senior Notes or the 3.00% Senior Notes; however, both are subject to cross-default provisions.

Credit Ratings

The Company’s credit ratings, which were independently developed by the following credit agencies, are detailed below:

• S&P Global Ratings affirmed the Company’s corporate credit rating of BBB (stable outlook) in August 2022.

• Moody’s Investors Service affirmed the Company’s corporate credit rating of Baa2 (stable outlook) in December 2021.

• Fitch Ratings reaffirmed the Company’s corporate credit rating of BBB+ (stable outlook) in April 2023.

Critical Accounting Estimates

As discussed in the Annual Report on Form 10-K for the year ended December 31, 2022, the preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. There have been no changes to the Company’s critical accounting estimates described in the Annual Report on Form 10-K for the year ended December 31, 2022.

35
T a b l e o f C o n t e n t s
Non-GAAP Disclosures

Set forth below are reconciliations of each of Organic net sales, Adjusted net income attributable to IDEX, Adjusted diluted earnings per share (“EPS”) attributable to IDEX, Consolidated Adjusted earnings before interest, income taxes, depreciation and amortization (“Adjusted EBITDA”) and Consolidated Adjusted EBITDA margin to its respective most directly comparable U.S. GAAP measure. Management uses these metrics to measure performance of the Company since they exclude items that are not reflective of ongoing operations, as identified in the reconciliations below. Management also supplements its U.S. GAAP financial statements with adjusted information to provide investors with greater insight, transparency and a more comprehensive understanding of the information used by management in its financial and operational decision making.

This report references organic sales, a non-GAAP measure, that excludes (1) the impact of foreign currency translation and (2) sales from acquired or divested businesses during the first 12 months of ownership or prior to divestiture. The portion of sales attributable to foreign currency translation is calculated as the difference between (a) the period-to-period change in organic sales and (b) the period-to-period change in organic sales after applying prior period foreign exchange rates to the current year period. Management believes that reporting organic sales provides useful information to investors by helping to identify underlying growth trends in the Company’s business and facilitating easier comparisons of the Company’s revenue with prior and future periods and to its peers. The Company excludes the effect of foreign currency translation from organic sales because foreign currency translation is not under management’s control, is subject to volatility and can obscure underlying business trends. The Company excludes the effect of acquisitions and divestitures because they can obscure underlying business trends and make comparisons of long-term performance difficult due to the varying nature, size and number of transactions from period to period and between the Company and its peers.

Management believes that Adjusted EBITDA, which is EBITDA adjusted for items that are not reflective of ongoing operations, is useful as a performance indicator of ongoing operations. The Company believes that Adjusted EBITDA is useful to investors as an indicator of the strength and performance of the Company and its segments’ ongoing business operations and a way to evaluate and compare operating performance and value companies within the Company’s industry. Management believes that Adjusted EBITDA margin is useful for the same reason as Adjusted EBITDA. The definition of Adjusted EBITDA used here may differ from that used by other companies.

This report also references free cash flow. This non-GAAP measure is discussed and reconciled to its most directly comparable U.S. GAAP measure in the section above titled “Free Cash Flow.”

The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures prepared in accordance with U.S. GAAP. Due to rounding, numbers presented throughout this and other documents may not add up or recalculate precisely . The financial results prepared in accordance with U.S. GAAP and the reconciliations from these results should be carefully evaluated.

1. Reconciliations of the Change in Net Sales to Organic Net Sales
Three Months Ended March 31, 2023
FMT HST FSDP IDEX
Change in net sales 18 % 11 % 6 % 13 %
- Net impact from acquisitions/divestitures 11 % 11 % — % 9 %
- Impact from foreign currency (2 %) (3 %) (3 %) (2 %)
Change in organic net sales 9 % 3 % 9 % 6 %



36
T a b l e o f C o n t e n t s
2. Reconciliations of Reported-to-Adjusted Net Income and Diluted EPS (in millions, except per share amounts)
Three Months Ended March 31,
2023 2022
Reported net income attributable to IDEX $ 139.8 $ 140.0
+ Restructuring expenses and asset impairments 0.5 —
+ Tax impact on restructuring expenses and asset impairments (0.1) —
- Gains on sales of assets — (2.7)
+ Tax impact on gains on sales of assets — 0.6
+ Acquisition-related intangible asset amortization 23.6 15.3
+ Tax impact on acquisition-related intangible asset amortization (5.2) (3.4)
Adjusted net income attributable to IDEX $ 158.6 $ 149.8

Three Months Ended March 31,
2023 2022
Reported diluted EPS attributable to IDEX $ 1.84 $ 1.83
+ Restructuring expenses and asset impairments 0.01 —
+ Tax impact on restructuring expenses and asset impairments — —
- Gains on sales of assets — (0.03)
+ Tax impact on gains on sales of assets — 0.01
+ Acquisition-related intangible asset amortization 0.31 0.20
+ Tax impact on acquisition-related intangible asset amortization (0.07) (0.05)
Adjusted diluted EPS attributable to IDEX $ 2.09 $ 1.96
Diluted weighted average shares outstanding 75.9 76.4





37
T a b l e o f C o n t e n t s
3. Reconciliations of Net Income to Adjusted EBITDA (dollars in millions)
Three Months Ended March 31, 2023
FMT HST FSDP Corporate IDEX
Reported net income $ — $ — $ — $ — $ 139.8
+ Provision for income taxes — — — — 40.0
+ Interest expense — — — — 13.1
- Other income (expense) - net — — — — 0.6
Operating income (loss) 96.5 77.5 46.0 (27.7) 192.3
+ Other income (expense) - net 0.5 (0.3) (0.2) 0.6 0.6
+ Depreciation 3.1 7.3 2.1 0.3 12.8
+ Amortization 6.0 15.9 1.7 — 23.6
+ Restructuring expenses and asset impairments 0.1 0.3 0.1 — 0.5
Adjusted EBITDA $ 106.2 $ 100.7 $ 49.7 $ (26.8) $ 229.8
Net sales (eliminations) $ 321.8 $ 351.0 $ 174.4 $ (1.8) $ 845.4
Net income margin 16.5 %
Adjusted EBITDA margin 33.0 % 28.7 % 28.5 % n/m 27.2 %

Three Months Ended March 31, 2022
FMT HST FSDP Corporate IDEX
Reported net income $ — $ — $ — $ — $ 139.9
+ Provision for income taxes — — — — 40.5
+ Interest expense — — — — 9.5
- Other income (expense) - net — — — — 2.3
Operating income (loss) 80.4 0.0 83.6 40.5 (16.9) 187.6
+ Other income (expense) - net 1.6 0.2 1.6 (1.1) 2.3
+ Depreciation 3.9 6.1 2.1 0.1 12.2
+ Amortization 3.7 9.9 1.7 — 15.3
- Gains on sales of asset (1.2) — (1.5) — (2.7)
Adjusted EBITDA $ 88.4 $ 99.8 $ 44.4 $ (17.9) $ 214.7
Net sales (eliminations) $ 272.0 $ 315.2 $ 164.7 $ (0.8) $ 751.1
Net income margin 18.6 %
Adjusted EBITDA margin 32.5 % 31.7 % 26.9 % n/m 28.6 %











38
T a b l e o f C o n t e n t s
Cautionary Statement Under the Private Securities Litigation Reform Act

This quarterly report on Form 10-Q, including the “Overview,” “Results of Operations” and “Liquidity and Capital Resources” sections of this Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, anticipated future acquisition behavior, availability of cash and financing alternatives, the intent to refinance or repay the Company’s 3.20% Senior Notes due June 2023 using the available borrowing capacity of the Revolving Credit Facility, the completion of pending transactions (including the acquisition of Iridian) and the anticipated benefits of the Company’s recent acquisitions, including the acquisitions of Nexsight, KZValve and Muon Group and are indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “guidance,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “management believes,” “the Company believes,” “the Company intends” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this report.

The risks and uncertainties include, but are not limited to, the following: levels of industrial activity and economic conditions in the U.S. and other countries around the world, including uncertainties in the financial markets and adverse developments affecting the financial services industry; pricing pressures, including inflation and rising interest rates, and other competitive factors and levels of capital spending in certain industries, all of which could have a material impact on order rates and the Company’s results; the impact of health epidemics and pandemics and terrorist attacks and wars, including the ongoing conflict between Russia and Ukraine, which could have an adverse impact on the Company's business by creating disruptions in the global supply chain and by potentially having an adverse impact on the global economy; the Company’s ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the Company operates; developments with respect to trade policy and tariffs; interest rates; capacity utilization and the effect this has on costs; labor markets; supply chain backlogs, including risks affecting component availability, labor inefficiencies and freight logistical challenges; market conditions and material costs; risks related to environmental, social and corporate governance issues, including those related to climate change and sustainability; and developments with respect to contingencies, such as litigation and environmental matters.

Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in the Company’s most recent annual report on Form 10-K and the Company’s subsequent quarterly reports filed with the Securities and Exchange Commission (“SEC”) and the other risks discussed in the Company’s filings with the SEC. The forward-looking statements included here are only made as of the date of this report, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.






















39
T a b l e o f C o n t e n t s
Item 3. Quantitative and Qualitative Disclosures About Market Risk

The Company is subject to market risk associated with changes in foreign currency exchange rates and interest rates as well as inflationary factors. The Company may, from time to time, enter into foreign currency forward contracts and interest rate swaps on its debt when it believes there is a financial advantage in doing so. A treasury risk management policy, adopted by the Board of Directors, describes the procedures and controls over derivative financial and commodity instruments, including foreign currency forward contracts and interest rate swaps. Under the policy, the Company does not use financial or commodity derivative instruments for trading purposes and the use of these instruments is subject to strict approvals by senior officers. Typically, the use of derivative instruments is limited to foreign currency forward contracts and interest rate swaps on the Company’s outstanding long-term debt. As of March 31, 2023, the Company did not have any derivative instruments outstanding.

Foreign Currency Exchange Rates

The Company’s foreign currency exchange rate risk is limited principally to the Euro, Swiss Franc, British Pound, Canadian Dollar, Indian Rupee, Chinese Renminbi, Swedish Krona and Brazilian Real. The Company manages its foreign exchange risk principally through invoicing customers in the same currency as the source of products. Foreign currency transaction gains and losses are reported within Other (income) expense - net in the Condensed Consolidated Statements of Income.

Interest Rate Fluctuations

The Company has interest rate exposure due to $279.4 million of the $1,479.5 million debt outstanding at March 31, 2023 being floating rate debt. The Company’s Revolving Credit Facility and Term Facility both bear interest at either an alternate base rate or adjusted Term SOFR (or appropriate alternative currency reference rates) plus, in each case, an applicable margin based on the lower of the Company’s senior, unsecured, long-term debt rating or the Company’s applicable leverage ratio. At March 31, 2023, there was $79.4 million outstanding under the Revolving Credit Facility with an interest rate of 3.32% and $200.0 million outstanding under the Term Facility with an interest rate of 5.83%.

Inflation Risk

The Company sources a wide variety of materials and components from a network of global suppliers. While materials are typically available from numerous suppliers, they are subject to price fluctuations, which could have a negative impact on the Company’s results. The Company seeks to minimize the effects of inflation and changing prices through price increases to maintain reasonable gross margins.

Item 4. Controls and Procedures

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

As required by SEC Rule 13a-15(b), the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, the Company’s Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of March 31, 2023.

There has been no change in the Company’s internal control over financial reporting during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

40
T a b l e o f C o n t e n t s
PART II. OTHER INFORMATION
Item 1. Legal Proceedings

The Company and its subsidiaries are party to legal proceedings arising in the ordinary course of business as described in Note 18 in Part I, Item 1, “Legal Proceedings,” and such disclosure is incorporated by reference into this Item 1, “Legal Proceedings.”

The Company’s threshold for disclosing material environmental legal proceedings involving a government authority where potential monetary sanctions are involved is $1.0 million.

In addition, the Company and six of its subsidiaries are presently named as defendants in a number of lawsuits claiming various asbestos-related personal injuries, allegedly as a result of exposure to products manufactured with components that contained asbestos. These components were acquired from third party suppliers and were not manufactured by the Company or any of the defendant subsidiaries. To date, the majority of the Company’s settlements and legal costs, except for costs of coordination, administration, insurance investigation and a portion of defense costs, have been covered in full by insurance, subject to applicable deductibles. However, the Company cannot predict whether and to what extent insurance will be available to continue to cover these settlements and legal costs, or how insurers may respond to claims that are tendered to them. Asbestos-related claims have been filed in jurisdictions throughout the United States and the United Kingdom. Most of the claims resolved to date have been dismissed without payment. The balance of the claims have been settled for various immaterial amounts. Only one case has been tried, resulting in a verdict for the Company’s business unit. No provision has been made in the financial statements of the Company, other than for insurance deductibles in the ordinary course, and the Company does not currently believe the asbestos-related claims will have a material adverse effect on the Company’s business, financial position, results of operations or cash flows.

Item 1A. Risk Factors

There have been no material changes with respect to risk factors disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

There were no share repurchases during the three months ended March 31, 2023. As of March 31, 2023, the amount of share repurchase authorization remaining was $ 563.8 million.
41
T a b l e o f C o n t e n t s
Item 6. Exhibits

Exhibit
Number 		Description
31.1*
31.2*
32.1*
32.2*
101* The following financial information from IDEX Corporation's Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 formatted in Inline eXtensible Business Reporting Language (iXBRL) includes: (i) the Cover Page, (ii) the Condensed Consolidated Balance Sheets, (iii) the Condensed Consolidated Statements of Income, (iv) the Condensed Consolidated Statements of Comprehensive Income, (v) the Condensed Consolidated Statements of Equity, (vi) the Condensed Consolidated Statements of Cash Flows, and (vii) Notes to the Condensed Consolidated Financial Statements.
104* Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
* Filed herewith.

42
T a b l e o f C o n t e n t s
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
IDEX Corporation
By: /s/ WILLIAM K. GROGAN
William K. Grogan
Senior Vice President and Chief Financial Officer
(Principal Financial Officer)
By: /s/ ALLISON S. LAUSAS
Allison S. Lausas
Vice President and Chief Accounting Officer
(Principal Accounting Officer)
Date: April 27, 2023
43
TABLE OF CONTENTS